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The thesis entitled ''Analysis of Drugs in Pharmaceutical Formulations" is 
comprised of five chapters. The first chapter describes a general literature survey of the 
subject matter. The very relevant matters include, (i) a brief discussion on analytical 
chemistry, its relation with our daily life from old age, role played in the field of 
pharmaceutical and biomedical analysis, (ii) various types of analytical techniques and 
procedures involving sophisticated instruments which are in use now a days, (iii) the 
validation of the developed method and (iv) the statistical treatments adopted during the 
data analysis to ensure and enforce the validity of method. 
It is well known that human shows briskness in every era of evolutions and 
development, which led to the birth of analytical chemistry. It deals with the study of the 
intrinsic properties of the materials to discover their valueable applicability or to warn the 
concerned one with the possibility of harm from them. Unlike, other areas of studies in 
science, there are different properties, which heavily influence the results of the analytical 
methodology at each and every step, thus having direct impact on the results. These 
important properties have been discussed. By the time, the demands of the biochemical 
sciences and the advancement of physical sciences opened the door of instrumentation in 
the field of analytical chemistry. The different types of well-established analytical 
techniques have been discussed. 
Before or during the development of a method, it is necessary to be very careful 
of certain important things. These concepts have been discussed briefly. Once the 
analytical method is adjusted, it is necessary to decide its suitability for the intended 
purpose. This is known as the method validation. Brief discussion of the validation and 
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its components has been presented. When deciding for validation of the method, the role 
of statistical analysis can not be ignored. It is the only way to get the most conclusive 
results from the mathematical data obtained during the analysis. It also helps to decide 
with the progress of the work at each step. A discussion of the statistical analysis has 
been given. A brief literature and classification of the concerned pharmaceuticals also 
presented. 
The second chapter describes kinetic spectrophotometric method for the 
determination of silymarin in pure form and in pharmaceutical formulations. The 
method is based on the oxidation of the drug with potassium permanganate at pH 
7.0±0.2. The reaction is followed spectrophotometrically by measuring the 
decrease in the absorbance at 530 nm. Under the optimum experimental 
conditions, a calibration curve was constructed by plotting logarithm of initial 
rate of reaction (log v) versus logarithm of silymarin concentration (log C), 
which was linear over silymarin concentration range of 18-50 |^ g ml'^ The linear 
regression analysis using the method of least square was made to evaluate the 
slope, intercept and correlation coefficient. The linear regression equation and 
correlation coefficient are log v = 1.024 log C + 3.235 and r = 0.9997 which 
indicates an excellent linearity. The confidence limits for the slope and intercept 
of the line of regression were calculated and found to be 1.024±3.96x10'" and 
3.235±1.67xl0"\ respectively. This indicated the high reproducibility of the 
proposed kinetic method. The proposed method was compared with the reference 
method. 
THESIS 
The third chapter deals with the four simple, sensitive and accurate 
spectrophotometric methods for the determination of nifedipine in pharmaceutical 
formulations. These methods are based on the formation of ion-pair complexes of amino 
derivative of the nifedipine with bromocresol green (BCG), bromophenol blue (BPB), 
biomothymol blue (BTB) and eriochrome black T (EBT) in acidic medium. The coloured 
products are extracted with chloroform and measured spectrophotometrically at 415 nm 
(BCG, BPB and BTB) and 520 nm (EBT). Beer's law was obeyed in the concentration 
range of 5-32.5, 4-37.5, 6.5-33.0 and 4.5-22.5 \xg ml"^  with molar absorptivity of 6.41 x 
10^ 4.85 X 10^ 5.26 x 10^  and 7.69 x 10^  L mol"^ cm"^  and relative standard deviation of 
0.82, 0.72, 0.66 and 0.68 % for BCG, BPB, BTB and EBT methods, respectively. These 
methods have been successfully applied for the assay of drug in pharmaceutical 
formulations. No interference was observed from common pharmaceutical adjuvants. 
Statistical comparison of the results with the reference method shows excellent 
agreement and indicates no significant difference in accuracy and precision. 
The fourth chapter describes two simple, sensitive and economical 
spectrophotometric methods for the determination of amiodarone hydrochloride 
in pure form and commercial dosage forms. Method A is based on the charge 
transfer complexation reaction of amiodarone base with p-chloranilic acid in 
dioxan- dichloromethane. The coloured product is measured at 535 nm. Method 
B also utilizes the charge transfer complexation reaction of amiodarone base with 
2,3- dichloro 5,6- dicyano 1,4- benzoquinone (DDQ) in acetonitrile medium, 
resulting in the formation of DDQ radical anion, which absorbs maximally at 570 
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nm. Beer's law was obeyed in the concentration range of 10 - 360 and 2 - 6 5 |j,g 
ml"^  for methods A and B, respectively. The molar combining ratio, association 
constant and optimum assay conditions were studied. The proposed methods 
have, been successfully applied to the determination of amiodarone in 
commercial dosage forms. The results are validated statistically and compared 
with the reference method. 
The fifth chapter deals with the two simple and sensitive spectrophotometric 
methods for the determination of verapamil hydrochloride in pure and commercial 
dosage forms. The first method is based on the oxidation of the drug with potassium 
metaperiodate in sulphuric acid medium to give coloured product, which absorbs 
maximally at 425 nm. The second procedure involves the formation of coloured 
chloroform extractable ion-pair complex of the drug with tropaeolin 000 at pH 4.0 
showing absorption peak at 400 nm. Under tlie optimized experimental conditions, Beer's 
law is obeyed in the concentration range of 0.00-187.5 and 2-30 |j,g ml"' for methods A 
and B, respectively. Both the methods are highly reproducible and have been successfully 
applied to the commercial dosage forms. Results of analyses were validated statistically 
and through recovery studies. Statistical comparison of the results with the reference 
method shows excellent agreement and indicates no significant difference in accuracy 
and precision. 
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CHapter -1 
Qenerat Introduction 
Medicine is a very ancient art, and drugs have been used in days of antiquity as 
far back as history can take us. The early explorers found the South American hidians in 
possession of Cinchona bark from which Pelletier and Caventou extracted the 
antimalairal alkaloids, quinine. The Roman Naturalist Galenus (131-200 A.D) said that 
proper herb mixture could be used for all conceivable health defects. In Galenus 
apothecary shop, herbs and some metallic drugs (copper and zinc ores, iron sulfate, 
cadmium oxide) were found in abimdance, and a semblance of assaying was maintained 
by insistence on "pure" drugs that is the right variety and age of botanical specimens. The 
intimation of dosage levels can be seen in his contention that powerfiil narcotics reUeve 
pain but may also cause death in excess. In 1646, the French physician Guy Palin (1602-
1672) suggested to a medical student; "Above all flee books on chemistry, in quorum 
lectione oleum et Perdes" . This attitude changed as exact laws of chemistry were 
formulated as the physiological action of well defined compounds become amenable to 
quantitative study and as the active principles of ancient - herbal drugs were extracted, 
purified and fitted into stoichiometric laws [1]. 
hi the mean time, new medicines were discovered and old ones improved. 
Withering (1741-1799) introduced digitalis (purple foxglove) as a therapeutic agent for 
dropsy, and almost the same material is used in the treatment of cardiac edema today. 
Van Swieten (1700-1772) taught the advantages of corrosive sublimate (mercuric 
chloride) over older mercurial preparations in "Fevers". Opium was dispensed and 
studied by de Quincey (1785-1859) "to tranquilize all irritations of the nervous system, to 
stimulate the capacity of enjoyment and to sustain the else drooping animal energies" [2]. 
Phenacetin, a pain killing drug, was the first pharmaceutical product 
developed by the German chemical company, Friedrich Bayer & Co; which, in 
1888, licensed May and Baker to manufacture and market it in the United 
Kingdom. Higher standards for the preparation of pharmaceutical ingredients had 
been set, following the 1858 Medical Act's stipulation that the General Medical 
Council (UK) should produce a list of medicines and compounds and manner of 
preparing them together with true weights and measures by which they are to be 
prepared and mixed [3]. The first British Pharmacopoeia was published in 1864 
and thereafter pharmaceutical and fine chemical manufacturers laid greater 
emphasis on meeting the standards it set. In 1890, Jesse Boot established an 
analytical laboratory and its staff were involved mainly for analyzing proprietory 
medicines of competitors in order that Boots should develop new and / or 
cheaper formulations [4]. 
Analj^ical Chemistry is the science and art of determining the 
compositions of materials in term of the elements or compounds contained in 
them. Historically, the development of analytical methods has followed closely 
the introduction of new measuring instruments. Among the many unprecedented 
and fundamental changes occurred in the Chemistry during the past century 
perhaps the most notable was the increase in the use of sophisticated instruments 
and techniques. Researchers in Pharmaceutical Chemistry by the applications of 
these techniques are adding a lot in the development of new drugs, which are 
improving the life expectancy but also presenting new challenges. 
Analytical Chemistry in pharmaceutics is indispensable, without the use of 
analytical techniques, it is impossible for the chemists or the researchers to 
develop a new approach to solve the problems of quality control and in 
ascertaining optimum experimental conditions to obtain a good yield of products. 
Development of new pharmaceutical product from naturally occurring 
substances undergoes a nimiber of steps from laboratory to semi scale synthesis, 
pilot plant scale up, efficacy and toxicology testing, clinical trials and finally full 
scale production. In order to safeguard public health, there should be constant 
monitoring of impvirities present in the form of inorganic and organic compounds 
in the pure drugs and in pharmaceutical formulations. From the last few decades, 
Analytical researchers continuing their efforts to produce high quality products 
by improving the existing methods of analysis. A very large number of examples 
can be cited where analytical chemistry find its applications to drug analysis in 
pharmaceutical preparations and biological samples. [5-7]. 
In pharmaceutical industry, the quality of the manufactured drug and its 
formulations must be carefully controlled. Slight changes in composition or in 
the purity of drug itself can affect therapeutic values. Therefore, it is necessary to 
establish the properties and therapeutic value of a drug before it is approved and 
made available in the market. Establishment of the permissible level of dosage of 
drug requires the determination of its composition, toxicity and its metabolite at 
various stages. 
The availability of sub-standard medicines to the general public possesses 
many problems, both clinically and economically. It is widely believed that such 
sub-standard preparations are readily available in many developing countries [8-
13]. This may be due to poor manufacturing procedures, poor storage conditions 
or deliberate counterfeiting of branded or generic products. Therefore, it is 
important to recognize that the drugs may contain impurities. These impurities 
may result from many sources like raw materials and regents, as reaction by 
products, and through degradation during manufacture and storage. Since the 
impurities can have safety and efficacy implications, and are therefore the subject 
of considerable attention by both manufacturers and regulatory agencies. 
Impurities can be classified into three groups, namely: organic, inorganic and 
residual solvents. Organic impurities may arise from starting materials, 
intermediates and synthetic by-products or from reagents and catalyst or as a 
consequence of degradation. Inorganic impurities may result from reagents, 
ligands or catalysts as heavy metals or inorganic salts. Residual solvents are 
inevitable in drug substance since without solvents, purification and generation 
of the desired crystal morphology would be impossible. However, since residual 
solvents also arise in excipients and occasionally in the manufacture of drug 
products, it was decided to draft a separate guideline to address appropriate 
levels. A key component of the guideline, and a fundamental concept is 
qualification. Qualification is defined as the process of acquiring and evaluating 
data, which establish the biological safety of the individual impurity or a given 
impurity profile at the level(s) specified. Thus, the pharmaceutical analyst and 
toxicologist must work hand in hand throughout the pre-clinical and clinical 
development programme in order to be able to set meaningful specification 
requirements. The pharmaceutical analyst must give the usefiil thoughts to the 
analytical methods, especially in the development phases. Therefore, it is an 
important task for the pharmaceutical analyst to choose an analytical technique 
with modem instrimientation, which provides the best solutions to the problems. 
The most commonly used analytical techniques in pharmaceutical analysis 
are described below. The chromatographic methods include paper 
chromatography, thin layer chromatography, column chromatography, capillary 
electrochromatography, high performance liquid chromatography, high 
performance thin layer chromatography and gas chromatography. The 
electrochemical methods mainly used for this purpose are polarography, 
volatammetry and amperometry. The radiotracer techniques include mainly the 
isotopic dilution and the activation analysis. The spectroscopic techniques used 
for this purpose are UV-visible spectrophotometry, derivative 
spectrophotometry, difference spectrophotometry, infirared spectroscopy, flame 
photometry, fluorometry and nuclear magnetic resonance. 
There are number of analysis that could not have been accomplished in 
any other ways except the use of chromatographic techniques. High performance 
liquid chromatographic methods have been successfully applied in drug analysis 
and have now appeared in the dissolution monographs of pharmacopoeias for the 
assay of drugs in dissolution fluids [14-16]. It is becoming increasingly popular 
because of its sensitivity and specificity in multicomponent analysis and widely 
used for the identification of drugs in plasma and drug formulations [17-37]. 
High performance thin layer chromatographic technique is flexible enough 
to analyze different kind of samples. It is an Off - Line technique whose every 
stage of analysis can be visualized. It can be used in pharmaceuticals, biomedical 
and environmental analysis. A review paper by Renger on contemporary thin 
layer chromatography and high performance thin layer chromatography in 
pharmaceutical quality control [38,39] discussed development and validation of 
methods. Advantages stated include simplicity of handling and performance; 
flexibility and short analysis time; the ability to analyze complex or crude 
samples with minimimi sample clean up; wide variety of layers; mobile phase; 
operational aspects; and detection reagents; no obligation for elution; ability to 
evaluate the entire chromatogram stored on the plate with a variety of techniques 
and parameters without time constraints; simultaneous but independent 
development of multiple samples and standards on each plate, leading to high 
sample throughput and increased reliability of results (in-system calibration); and 
robustness, allowing easy transfer and adoption of methods. Several drugs have 
been investigated by high performance thin layer chromatography in 
pharmaceutical preparations [40-49]. 
Capillary electrochromatography is a method in which a liquid mobile 
phase is driven through a stationary phase in a packed capillary column by the 
electro-osmotic flow generated by a large difference in potential across the 
column [50-53]. A number of papers have appeared that discuss various aspects 
of this technique, including one that considers the use of open-tubular capillaries, 
packed capillaries and monolithic capillaries [54]. 
Capillary electrophoresis technique continues to grow in popularity 
especially in areas where they can provide complementary informations to the 
other more established methodologies or advantages in selectivity and efficiency 
[55]. Two of the areas where usage has increased the most are in assessing 
enantiomer purity of pharmaceutical via the addition of chiral additives [56,57], 
and in determining the physiochemical information about the analyte. Another 
important aspect of this technique is that flow volumes are small, and as such, 
coupling it to a mass spectrometer is relatively easy [58,59]. A consideration that 
is especially important for a technique to gain acceptance in the pharmaceutical 
industry is validation [60,61]. The results generated in electrophoresis technique 
are comparable to HPLC and GC in terms of accuracy, precision, linearity and 
range, specificity and ruggedness. 
Flow injection analysis is widely used as analytical technique [62,63] and 
has several advantages: (1) reduced reagent consumption, (2) high sampling 
frequency and (3) safety in applying toxic reagents because the whole analysis 
proceeds in a closed system. An additional advantage observed in flow -
injection analysis is increased selectivity when the analyte is accompanied by 
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more slowly reacting components. Flow injection analysis has been applied in 
the analysis of several pharmaceutical compounds [64-73]. 
Electrochemistry can be used at the early stage of the drug researches for 
screening the pharmacological activity of a homologous series of newly 
synthesized molecules. There are several examples in the literature showing the 
relationship between the electrochemical data and the pharmacological properties 
of drug [74-77]. Electrochemical behavior of cefetamet sodium has been studied 
using dc, ac, and differential pulse polarography, cyclic voltammetry and 
constant potential electrolysis [78]. Likewise, the electrochemical oxidation of 
cefotaxime at activated glassy carbon, platinum, and carbon paste electrodes has 
been examined [79]. Square wave voltammetry has been used to determine 
sulphamethoxypyridazine and trimethoprim simultaneously in mixtures [80]. 
The antihypertensive drug doxazosin in urine and formulations was 
determined by means of both, differential pulse and square wave adsorption 
stripping voltammetry at a mercury drop electrode [81]. The potential of electro 
analytical techniques for pharmaceutical analysis, covering a broad spectrum of 
electrochemical techniques, was reviewed by Kauffmann et al. [82]. 
Analytical absorption spectroscopy in ultraviolet and visible region of 
electromagnetic spectrum is widely used for quantitative analysis in the field of 
pharmaceutical and biomedical analysis. The scope of absorption spectroscopy is further 
extended by use of colour reactions often with concomitant increase in sensitivity and or 
selectivity. Such reactions are used to modify the spectrum of an absorbing molecule, so 
that it could be detected in visible region well separated from other interfering 
components. Chemical modification is also useful for transforming non-absorbing 
molecule to a stable derivative possessing significant absorption spectral behaviour. 
A particular advantage of UV Spectrophotometry is that it does not destroy the 
sample. After recording the ultra violet spectrum, one can reextract the solution and 
recover the absorbing substances for subsequent analytical procedures, which is in sharp 
contrast to gas chromatographic and immunological procedures. UV- spectrophotometric 
methods are simple, quick, economical and usually do not require elaborate preparation 
step prior to assay. However, a UV method is not adequate when two or more drugs with 
similar UV spectra are present in the sample or excipients or decomposition product 
exhibits UV interference, as in case with dissolution testing of Phenytoin capsules [83]. 
When a beam of light is passed through material, the incident radiation (IQ) will 
always be more intense than the convergent radiation (I). Attenuation of the incident 
radiation may be attributed to (1) reflections at the interfaces between air and cell wall 
and sample and cell wall, (2) scattering by any suspended particles or dust in the sample 
and (3) absorption of radiation by the sample, in normal applications light absorption is 
the primary factor reducing the incident radiation. 
Fluorescence can often increase the apparent intensity of the emergent radiation, 
which may result in inaccurate absorption measurements. Effect of fluorescence can be 
reduced by chemically inhibiting fluorescence, locating the sample some distance from 
the detector, or using appropriate cutoff filters to block the fluorescence occurring at 
longer wavelengths than the incident radiation. When using monochromatic light, the 
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fraction of the radiation absorbed by the substances, ignoring losses due to reflections and 
scattering, will be function of the concentration of the substance in the light path and the 
thickness of the sample. Mathematically this function can be defined as: A = Log [lo/I] = 
ebc, where A is defined as absorbance of the sample, "e" is wavelength dependent 
proportionality factor called molar absorptivity, "b" is the light path length through the 
sample and "c" is the concentration of the sample in appropriate units. The expression A 
= ebc is known as Lambert-Beer's law or Beer's law. 
The linearity of Beer's law is subject to some restrictions. Concentrations may not 
always be directly proportional to absorbance. Chemical and physical interactions and 
instrumental limitations can produce deviations, particularly at high concentrations or 
high absorbance. Sample scattering, fluorescence, decomposition, and saturation are 
examples of sample-related problems affecting linearity. Hydrogen bonding, ion-pair 
formation, solvation and chemical reactions can cause incorrect calculations of sample 
concentration as the solvent concentration is varied. Instrument factors that can effect 
apparent deviation firom linearity are stray light, resolution and both absorbance and 
wavelength calibration. Most of the chemical and instrument effects described above will 
result in suppression of absorbance as concentration is increased. To prevent errors. 
Beer's Law plots should be constructed for each sample system with at least three points 
within the expected concentration range of the unknowns. 
Simple colorimetric and UV methods continue to be popular for carrying out 
single component assay on a variety of formulated products. Representative examples of 
some of the many assays that have been published are given in Table 1.1. Colorimetric 
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methods based on charge transfer reaction of certain n - acceptors have been successfiilly 
utilized in pharmaceutical analysis. The u-acceptors such as p-Chloranilic acid, 
dichlorophenyl-indophenyl, 2,3-dichloro 5,6-dicyano p-benzoquinone, 
tetracyanoethylene, tetrachlorobenzoquinone, p-benzoquinone, p-nitrophenol, 
tetracyanoquinodimethane [140-141] have been used to carry out spectrophotometric 
assay of certain cardiovascular drugs such as amlodipine besylate [89,90], verapamil 
hydrochloride, atenolol [96], acebutalol hydrochloride, carazol, propranolol 
hydrochloride [142] and lisinopril [115]. 
Acid dyes, solochrome dark blue, solochrome black T, bromothymol blue, 
bromophenol blue, bromocresol green, bromocresol purple, sunset yellow, tropaeolin 000 
and indigo carmine form ion-pair complexes with basic drugs which were quantitatively 
extracted into chloroform. Colorimetric methods based on dye pairing continue to be 
important and have been used to assay compoimds such as amlodipine besylate [143-
145], verapamil hydrochloride [146], phenothiazine derivative [147] and famotidine 
[148]. 
Derivative Spectrophotometry is an analytical technique of great utility for 
extracting both qualitative and quantitative information from spectra composed of 
unresolved bands. In recent years, the introduction of electronic differentiation by a 
microcomputer interfaced with the spectrophotometer makes possible the plotting of the 
first, second or higher order derivatives of a spectrum with respect to wavelength. 
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Table 1.1. Assay of drugs in drug formulations by Spectrophotometric 
procedures. 
Name of Drug 
Acetaminophen 
Alendronate 
Amoxycillin 
Amlodipine besylate 
Ascorbic acid 
Aspirin 
Astemizol 
Reagents used 
p-xylenol 
Potassium hexacyanoferrate (HI) and 
m-cresol 
FeCla 
KIO3 
Tris- (o-phenanthroline) iron (II) 
Ninhydrin 
2,3-Dichloro 5,6-dicyano 1,4-
benzoquinone 
Ascorbic acid 
l-Chloro-2, 4-dinitro benzene 
NaOH 
p-Chloranilic acid 
Suprachen Violet 3B 
Tropaeolin 000 
Iron (III) and 1,10-Phenanthroline 
Amax(nm) 
635 
260 
520 
510 
590 
5S0 
530 
380 
302 
540 
590 
500 
515 
References 
[84] 
[85] 
[86] 
[87] 
[88] 
[89] 
[90] 
[90] 
[91] 
[92] 
[93] 
[94] 
[94] 
[94] 
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Acetic acid & N-bromosuccinimide 540 
Atenolol 
Benidipine 
hydrochloride 
Bromazepam 
Chlorhexidine 
Cisapride 
HCl & Celestine blue 
Iodine 
Chloranil 
2,3-Dichloro-5, 6-dicyanol, 4-
benzoquinone 
Bromanil 
Tetracyanoethylene 
Ciprofloxacin 
p-Chloranilic acid 
Methanol 
Mohr salt 
Alizarin yellow G. 
Chromotropic acid 
Phloroglucinol 
p-Chloranilic acid 
540 
Folin - Ciocalteau reagent & NaOH 720 
Glycine buffer and Azocarmine G 540 
365 
440 
470 
450 
450 
7,7,8,8-Tetracyanoquinodimethane 420 
535 
238 
584 
405 
530 
450 
520 
[95] 
[95] 
[95] 
[95] 
[96] 
[96] 
[96] 
[96] 
[96] 
[96] 
[97] 
[98] 
[99] 
[100] 
[101] 
[101] 
[120] 
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Desipramine 
Diltiazem 
Hydrochloride 
Doxorubicin 
hydrochloride 
L-Dopa 
Etidocaine 
Famotidine 
Flurazepam 
Gentamicin 
Imipramine 
Levopoda 
Lisinopril 
Tetracyanoethylene 
Anunonium metavandate 
Diclofenac Sodium Tris buffer 
Sodium metavandate 
Bromocresol green 
Bromothymol blue 
Bromophenol blue 
Ferric ammonium sulphate 
NaOH 
Bromocresol green 
Alkaline KMn04 
Ninhydrin 
HCl 
Ninhydrin 
Ammonium metavandate 
Cerium (IV) nitrate 
l,Fluoro-2, 4-dinitro benzene 
535 
618 
284,305 
750 
415 
415 
415 
[102] 
[103] 
[104] 
[105] 
[106] 
[106] 
[106] 
510 [107] 
300 
625 
610 
590 
230 
400 
618 
510 
356 
[108] 
[109] 
[110] 
[111] 
[112] 
[113] 
[103] 
[114] 
[115] 
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Loperamide 
hydrochloride 
Loratadine 
Meclozine 
hydrochloride 
Methyl dopa 
Mefloquine 
hydrochloride 
Mefenamic acid 
Menadione 
Metoprolol tartarate 
Chloranil 
Iodine 
Bromothymol Blue 
Bromophenol Blue 
Naphthol Blue Black 
Bromophenol Blue 
Chromotrope 2B 
Chromotrope 2R 
Cerivim (IV) nitrate 
HCL 
p-Dimethylaminocirmamaldehyde 
NaOH 
Ethylacetoacetate 
3-Methyl 2-benzothiazolinone 
hydrazone 
Tetracyanoethylene 
7,7,8,8-Tetracyanoquinodimethane 
346 
295 
414 
415 
627 
415 
540 
528 
550 
222 
665 
450 
550 
625 
450 
420 
[116] 
[117] 
[117] 
[117] 
[117] 
[118] 
[119] 
[119] 
[114] 
[120] 
[121] 
[122] 
[123] 
[124] 
[125] 
[125] 
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Nalidixic acid 
Nifedipine 
Nimisulide 
Nitrazepam 
Nizatidine 
Nortriptyline 
Hydrochloride 
Oxprenolol 
Piroxicam 
Salbutamol 
Trimethoprim 
Thyroxine sodium 
Tenoxicam 
Verapamil 
hydrochloride 
Persulphate in alkaline medium 
4-(Methyl amino phenol) and 
K2Cr207 
BCMn04 
Iminodibenzyl 
3-Aminophenol 
Ethylacetoacetate 
Alkaline KMn04 
3-Methyl 2-benzothiazolinone 
hydrazone 
Cerium (TV) in H2SO4 
Alizarin 
2,6-Dichloroquinone chlorimide 
7,7,8,8-Tetracyanoquinodimethane 
Persulphate in alkaline medium 
Nitrous acid 
Alizarin 
Chloramine-T 
320,390 
525 
530 
600 
470 
482 
610 
619 
480 
538 
602 
842 
355 
420 
538 
425 
[126] 
[127] 
[128] 
[129] 
[129] 
[130] 
[131] 
[132] 
[133] 
[134] 
[135] 
[135] 
[136] 
[137] 
[138] 
[139] 
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The derivative method has found applications not only in UV-spectrophotometry 
but also in infrared [149], atomic absorption, flame spectrophotometry [150,151], and 
fluorimetry [152,153]. The use of derivative spectrometry is not restricted to special 
cases, but may be of advantage whenever quantitative study of normal spectra is difficult. 
Its advantage is that the differentiation degrades the signal-to-nose ratio, so that some 
form of smoothing is required in conjunction with differentiation [154]. 
dA For a single-peak spectrum, the first-derivative is a plot of the gradient — of the 
UA 
absorption envelope versus wavelength and features maximum and minimum; the vertical 
distance between these is the amplitude, which is proportional to the analyte 
dA 
concentration; theoretically, — is zero at m^ax for the band in the normal spectrum. The 
dX 
d^A 
second-derivative spectrum, —r- versus wavelength, has two maxima with a minimum 
dX 
between them, at X,max of the normal absorption band [155]. In principle, both peak-
d'^A heights (measured from —^= 0) are proportional to the analyte concentration but the 
dX 
amplitude can also be measured by the so-called tangent method, in which a tangent is 
drawn to the maxima and amplitude is measured vertically from tangent to the minimum 
[156]. The differentiation discriminates against broad bands, emphasizing sharper 
features to an extent that increases with increasing derivative order, because for bands 
(Gaussian or Lorentzian) the amplitude Dn of the nth derivative is related to the n* power 
of the inverse of the band width, W, of the normal spectrum [157]: 
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D„a 
Thus, for two bands A and B of equal absorbance but different width, the 
derivative amplitude of the sharper band (A, for example) is greater than that of the 
broader (B) by a factor that increases with increasing derivative order [158,159]: 
For the reason, the use of derivative spectra can increase the detection sensitivity 
[160-162] of minor spectral features. For quantitative analysis, if Beer's law is obeyed for 
normal spectrum, the following equation can be obtained: 
= Ic 
dX" dA" 
Where A = Absorbance, e = molar absorptivity, / = cell path- length and C = 
concentration of the analyte and this forms the basis of analytical determinations [163]. 
Derivative Specti'ophotometry has been applied for quantification of drugs in 
pharmaceutical preparations [164-171]. 
Difference spectrophotometry is a technique, which requires high potentiometric 
accuracy and linearity. Small spectral changes in solutions with high initial absorbance 
are often measured. This technique has been extensively used in the determination of 
drugs by eliminating specific interference from degradation products, coformulated drugs 
[172], and also the non-specific irrelevant absorption from the formulation matrix 
[173,174]. It provides a sensitive method for detecting small changes in the environment 
of chromophores. In general, two solutions at the same concentration are directly 
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compared. One solution is selected as sample, the second as the reference. All coinmon 
spectral features to the two solutions cancel out. Only bands, which have been displaced 
in one solution relative to the other because of environmental differences, are recorded. 
Another emerging trend has been the increasing use of near-infrared (NIR) 
spectroscopy in the quality assurance and in process analysis of pharmaceutical products. 
Both qualitative and quantitative aspects of NIR spectroscopy as well as uses related to 
validation of procedures that employ it are discussed [175-177]. 
Other important emerging technologies in drug development are proteomics [178] 
combinatorial chemistry [179], the application of molecularly imprinted media [180,181], 
the use of light scattering particle size analysis for flocculated suspensions [182], and the 
profiling of monomeric and dimeric impurities in bulk pharmaceutical batches by 
^^FNMR[183]. 
The number of applications of kinetics to analytical chemistry continues to grow 
at a rapid pace. Kinetic methods are good choices for drug analysis as they permit the 
sensitive and selective determinations of many drugs within a few seconds with no 
sample pretreatment is many cases. Kinetic methods, because of its superiority to the 
other colorimetric methods due to the formation of unstable colours in some of these 
colorimetric ones, are among the first choices of the researchers in analytical chemistry. 
Moreover, the instrumentation required is generally very simple. The principles and 
applications of the kinetic methods have been reviewed in papers [184-192] and books 
[193,194]. Essentially kinetic methods rely on measurements of concentration changes 
(detected via signal changes in a reactant which may be the analyte itself) with time after 
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the sample and reagent have been mixed. The sample and reagent can be mixed manually 
or automatically, only slow enough reactions tolerate manual mixing and, even so, they 
may be better handled automatically, not only to obtain more rapid and reproducible 
results, but also to increase the reaction rate in some cases. Kinetic automatic techniques 
are generally based on open system, among the most popular of which is stopped flow 
(SF) system and the continuous addition of Reagent (CAR) Technique [195-198]. Several 
drugs have been determined by using CAR technique Math photometric [199-200] and 
fluorimetric [201] detection. The application of micellar systems to kinetic methods was 
the subject of a review by Cai and Co-workers [202]. The discussion included 
characteristic of micellar catalysis, micellar modification of properties of system, and 
application of micelles in multicomponent determinations. CuUen and Crouch [203], have 
described the application of multivariate calibration techniques to multicomponent 
kinetic based determinations. These techniques are mandatory for fast reactions but can 
also be extended to slow reactions. In both cases, the kinetic curve (variation of the 
analytical signal with time) can be recorded immediately. The slope of the initial straight 
portion of the kinetic curve gives the reaction rate, which is proportional to the analyte 
concentration (initial rate method). The fixed time method [204], also frequently used to 
determine the concentration involving the measurement of the signal (the value of which 
depends on the analyte concentration) at a preset time. 
The determinations can be implemented by using combinations of the SF 
technique with (a) fluorescence polarization immunoassay (FPIA), (b) micelle-stabilized 
room temperature phosphorimetry and (c) a sensitized energy transfer fluorescence 
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reaction, among other, all are novel strategies which have so far yielded excellent results 
in drug analysis. On the other hand, the CAR technique has been extended to 
chemiluminescence (CL) reactions as CAR chemiluminescence spectrometry (CARCL), 
a new approach that has proved outstanding for the analysis of drugs and other substances 
of analytical mterest. Moreover, new kmetic Ghemomettic (kinetometric) approaches 
[189] such as the Kalman filter have been developed and applied to the simultaneous 
determination of various compounds of pharmaceutical interest. 
Over the last few years the term chemometrics has been increasingly used. The 
organic chemist S. Wold supposedly coined this term in 1972 when submitting a grant 
proposal for the application of statistical methods to chemical data. Together with 
American analytical chemist B.R. Kowaiski, Wold formed the international 
chemometrics society. Subsequently there have been several major reviews, [205-208] 
ACS symposia [209,210], a National Bureau of standards conference, [211] a Nato 
School, [212], a text book [213] and a series of monographs [214] devoted to 
"Chemometrics". Recently two international journals devoted to Chemometrics have 
been established [215,216]. A large variety of clustering methods [217] have been 
developed, originally as aid to pharmaceutical and clinical researchers. The ability of 
modem analytical instruments helps a lot to acquire large amounts of data rapidly. In a 
modem laboratory, measurements are cheap compared with samples: many parameters 
(e.g.. Chromatographic and Spectroscopic peak intensities) can be obtained from each 
sample. Hence new approaches are needed to interpret what may be described as large 
multivariate data matrices, involving specialized statistical and computatioual rricthods, 
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clearly we can say that chemometrics involves the application of statistical methods to 
analytical data. 
Method Validation 
Method validation is an important component in determining the reliability and 
reproducibility of analytical method and is a reqiiirement of any regulatory submission 
[218], According to the European Union directives in referring to the Good 
manufacturing Practice and Quality control of drugs [219-221], validation must be 
applied not only in manufacturing process but also in analysis and control methods. The 
validation of analytical procedures used for raw materials and a finished product is 
gathered in the Pharmaceutical Products and Multistate Register [222-224] also and more 
recently it has been reviewed for ICH Harmonized Tripartite Guideline [225,226]. As far 
as the validation characteristics are concerned, if the analytical method is described in 
Pharmacopoeia, it will be proceeded as follows: (a) with regard to raw materials assay, 
the validation will not be necessary, although it must be checked before its routine use, 
enclosing information about linearity, sensitivity, precision and selectivity, (b) with 
regard to the finished product assay, it is necessary to carry out a brief validation to 
demonstrate that the precision, selectivity and accuracy are appropriate. 
Validation and Strategy 
The overall validation strategy consists of four components, which are the 
prevalidation, validation proper, study proper and statistical analysis. These components 
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constitute the platform to evaluate the reliability and ruggedness of an analytical method. 
Prevalidation 
Prior to initiating the validation proper, a prevalidation is performed by the 
primary analyst. This component provides the analyst an opportunity to obtain some 
practical experience v^th the methods and helps to identify the optimum conditions. It is 
recommended that the following studies be conducted prior to initiating the validation 
proper. The appropriate peak response to use in quantitating drug concentrations should 
be selected first. The optimum standard curve range and the number of calibrators should 
be established. The appropriate regression model which best fits the data is then selected. 
The extraction scheme and its recovery should be optimized to give insight into 
the limit of quantitation and to help determine if the extraction procedure is reproducible. 
If possible, potential compounds that could interfere with the method should be 
evaluated. The remaining system suitability parameters are then investigated by 
optimizing the other factors. 
Validation Proper 
The validation proper consists of four analytical runs generated on separate days. 
Each validation run emulates the analytical conditions of the study proper and its 
expected run time. This strategy helps the analyst develop a daily routine to use during 
the study proper and anticipate potential assay problems. Suggestions for additional 
samples to be analyzed during each validation run include samples fortified with 
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metabolites and potentially interfering compounds to identify response behaviour and 
ensure assay specificity. Stability samples to begin generating information pertinent to 
sample processing and storage. From the data generated, specific analytical parameters 
are reported, including linearity, accuracy, precision, sensitivity and recovery. From each 
standard curve; the slope, intercept, correlation coefficient and variance are monitored. 
Statistical analysis are used to determine with in and between-run variance and to 
demonstrate how the method can be expected to perform on a daily basis. Based on the 
mitial quality control data concentration results, acceptance criteria are established. 
Subsequent analytical runs are monitored during the study proper usmg these acceptance 
criteria to determine if the data generated are valid. 
Acceptance criteria for validation parameters 
Using the ICH guidelmes as a basis [227,228], it is the responsibility of the 
analyst to select for the given individual test procedure relevant parameters and 
appropriate acceptance criteria and to design the experimental studies accordingly. These 
acceptance criteria can often be derived from specification limits. 
As a general rule, the standard deviation of the analytical procedure should be 
lower than 1/6 of the specification range. A detailed approach taking the number of 
repeated determinations into account is based on confidence intervals [229,230]. Basic 
specification limits (BL) include the variability of the manufacturing process and 
represent the final limits (SL) if an error-free analytical procedure is used. Describing the 
analytical variability as a normal distribution of the experimental results, confidence 
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intervals can be constructed as a representation of the result probability for a given 
number of replicates. The combination of the basic limit and the limit (upper or lower) of 
the 95% confidence interval (one sided) then represents the overall specification limit 
(Eq. 1). 
SL = BL±t„_, 095^^ Eq.(l) 
It must be taken into account that this calculation is based on the true standard 
deviation whereas the standard deviation obtained in a validation study is only a random 
estimate which also displays a variability. A reliable experimental determination of the 
true value requires repeated intermediate precision studies, but it can be estimated from 
the statistical (z^) distribution of standard deviations. The upper 95% confidence limit of 
this distribution (UL) will represent the maximum value for the true standard deviation 
(Eq. 2). For six experimental values, it can be approximated by twice the experimental 
standard deviation [230]. 
UL(S,^e) = S,^,x U ^ Eq.(2) 
V Z "-' J0.95 
Rearranging Eqs. (1) and (2) gives the maximum permitted experimental standard 
deviation for the given specification limits, i.e. the acceptance limit for the validation. For 
drug substances, due to the presence of impurities, these are the lower limits. As the 
required standard deviation is dependent on the number of repetitions in the assay, 
adjustments are possible (Table 1.2.). Thus, the number of repeated determinations can 
also be fine-tuned according to the results of the validation. In case of sufficiently wide 
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specification limits compared to the analytical variability, this allows an efficiency 
optimization of the analytical procedure. 
While in the case of a drug substance assay the basic limits are defined mainly by 
the sum of impurities, in the case of drug products, often only estimation is possible. For 
simple dosage forms, the same variability may be expected for analytics and 
manufacturing. It should be noted that the estimation of the true standard deviation would 
result in a maximum value and, therefore, reduce the required acceptance limit. 
Consequently, in critical cases an experimental determination (using at least four to six 
series) might be reasonable to obtain an estimate for the true standard deviation. If 
specification limits are not yet defined or implied due to safety requirements, Eq. (1) can 
be used directly to calculate the lunits. For the true standard deviation, the upper limit of 
the experimental determination (Eq. 2) can be calculated or twice this value as an 
approximation. Alternatively, a soundly based intermediate precision may be used as 
estimation for the true standard deviation. 
With respect to impurity detenninations, the ICH reporting threshold of 0.05% 
[231] can be regarded as the required quantitation limit for unknown impurities, which 
would guarantee a reliable quantitation at the specification limit of 0.1%. If other limits 
are required due, for example, to safety considerations, the above-mentioned approach 
can be applied. Statistical tests such as the student's Mest or the evaluation of 95% 
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Table 1.2. Maximum permitted standard deviation for assay determinations in 
dependence on the number of repetitions and the specification range 
Drug product (%) Drug product (%) Drug product (%) 
Specification range 95-105 95-105 98-102 
Basic limit (lower) 97.5 (estimated) 99.0 (estimated) 99.5 (sum of impurities) 
Niraiber of repetitions Acceptance limit for experimental standard deviation in validation (n=6) 
2 0.28 0.45 0.17 
3 
4 
6 
0.74 
1.06 
1.44 
1.19 
1.7 
2.3 
0.45 
0.64 
0.86 
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confidence intervals should only be carefully (directly) applied as acceptance criteria 
because they test for statistical differences. Due to sometimes abnormally small 
variabilities in the analytical series, differences are identified as significant which are of 
no practical relevance [232]. In addition, when comparing independent methods for the 
proof of accuracy, different specificities can be expected which add a systematic bias, 
thus increasing the risk of the aforementioned danger. 
In addition, the power of these tests increases with the number of determinations. 
For practical purposes, a sufficient agreement between two results (two means or a mean 
and a nominal value, e.g. recovery) is completely adequate. The acceptance criteria can 
be derived from previous experience or calculated based on specification limits and 
statistical considerations. For example, assuming an assay procedure with specification 
limits from 95 to 105%, a recovery range from 98 to 102% would be acceptable. 
The acceptance criteria and limits should be defined before starting the validation 
and included in a protocol. After the validation studies, they will serve as a basis for the 
evaluation. 
Validation characteristics 
When performing validation studies, the whole analytical procedure including all 
the steps of the sample preparation should be applied, as far as possible. In contrast, the 
term 'method' should be restricted to the mode of analytical determination alone (e.g. 
capillary electrophoresis, (reversed phase) chromatography and spectrometry). Allowed 
exceptions to the written procedure concern the number of repetitions as the number of 
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determinations for the various validation characteristics is described in the ICH guideline 
(Table 1.2) and the repetitions in the procedure may be fine-tuned based on the validation 
results. Such an adjustment may also be used for the final calibration mode. 
As far as possible, the analytical procedure should be independent of the actual 
equipment used provided that the equipment has been appropriately qualified. This must 
be taken into account for the validation studies. 
Specificity 
There has been some controversy regarding the technical term for this validation 
characteristic, i.e. specificity versus selectivity [233]. In contrast to an isolated test 
procedure, in pharmaceutical analysis the sum of various control tests and hence there 
combined specificity is used for the overall batch evaluation. A very pragmatic definition 
describes selectivity as the (physical) separation of substance mixtures with, for example, 
chromatography and electrophoresis, i.e. the determination of the analyte in addition to 
other substances. The individual determination of an analyte in the presence of other 
substances, (i.e. without significant influence of other substances or classes of 
substances) is defined as specific by, for instance, mass spectrometry, NMR, infrared, 
fluorescence or UV spectrometry, electrochemical detection and titration [234]. 
With respect to chromatographic techniques, specificity can be demonstrated by a 
sufficient separation of the substances present. For the assay, appropriate separation 
means an adequate resolution between the main peak and the impurity and placebo peaks, 
which need not to be separated fi-om each other. The required resolution is strongly 
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dependent on the difference in the size of the corresponding peaks as well as on their 
elution order [235]. 
Linearity I range 
A linear dependence of the signal and the analyte concentration is certainly the 
most convenient case and widely used in pharmaceutical analysis. The requirements and 
relevant parameters for the various calibrations are given in Table 1.3. 
It should be noted that in most cases only a qualitative statement is needed. For 
example, if a single-point calibration (external standard) is aimed at, the requirements are 
a linear response flmction and the zero intercept. Care should be taken to remain within 
the linear range of the individual detector used. 
Accuracy 
The ICH guideline recommends the demonstration of accuracy over the whole 
working range (Table 1.4). However, if only a narrow range is required (e.g. assay or 
impurities with a low specification limit), a six-fold determination at a 100% test 
concentration as described for the precision studies may also be used. Several approaches 
discussed in the ICH guidelines are given in Table 1.5. If the analytical test to be 
validated is compared with another procedure or applied to a reference substance, the 
probably different specificities must be taken into account. Therefore, statistical tests 
should be performed only if the systematic bias based on these differences can be 
quantified and thus corrected or are negligible. Otherwise, the comparison should be 
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Table 1.3 Requirements for different calibration modes with relevant parameters 
Quantitation Requirements Relevant parameters 
Single-point calibration 
External standard Linear function 
Non-significant 
Ordinate intercept 
Homogeneity of variances" 
Multiple-point calibration 
Linear, unweighted Linear function 
Linear, weighted 
•Non-linear 
100%-method(area 
normalisation for 
impurities): 
Homogeneity of variances^ 
Linear function 
Continuous function 
For main peak: 
Linear function 
Non-significant 
Ordinate intercept 
Homogeneity of Variances" 
For impurities 
Linear Function 
Standard error of slope (residual standard deviation), 
Sensitivities (relative standard deviation, graph), 
residual analysis, statistical tests (vs. quadratic 
regression) 
Inclusion of zero in confidence interval of the 
ordinate intercept, magnitude of the intercept (as 
percent of the signal at 100% test concentration) 
F-test of the variances at the lower and upper limit of 
the range 
Standard error of slope (residual standard deviation), 
sensitivities (relative standard deviation, graph), 
residual analysis, statistical tests (vs. quadratic 
regression) 
F-test of the variances at the lower and upper limit of 
the range 
Standard error of slope (residual standard deviation), 
sensitivities (relative standard deviation, graph), 
residual analysis, statistical tests (vs. quadratic 
regression) 
Appropriate equation 
Standard error of slope (residual standard deviation), 
sensitivities (relative standard deviation, graph), 
residual analysis, statistical tests (vs. quadratic 
regression) 
Inclusion of zero in confidence interval of the 
ordinate intercept, magnitude of the intercept (as 
percent of the signal at 100% test concentration) 
F-test of the variances at lower and upper limit of the 
range 
Standard error of slope (residual standard deviation), 
sensitivities (relative standard deviation, graph), 
residual analysis, statistical tests (Vs. quadratic 
regression) 
May be presumed for a limited range (factor 10-20). 
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Table 1.4. Validation characteristics normally evaluated for the different types of test 
procedures and the minimum number of determination required 
Validation 
characheristics 
Specificity 
Linearity 
. Range 
Accuracy 
Precision 
Repeatability ' 
Intermediate 
precision 
reproducibility'^ 
Detection limit 
Quantitation limit 
Minimum number 
5 concentrations 
9 determinations over 3 
concentrations levels (e.g. 
3x3) 
6 determinations at 100% 
or 9 determinations over 3 
concentrations levels 
(e.g.3x3) 
2 series 
Test procedure 
Identity 
Yes 
No 
No 
No 
No 
No 
No 
No 
Impurities 
Quantitative 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No^  
Yes 
Limit 
Yes 
No 
No 
No 
No 
No 
« 
Yes 
No 
Assay^ 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Including dissolution content/Potency. 
^Lack of specificity of one analytical procedure could be compensated by other supporting analytical procedure. 
"Intermediate precision sufficient for submission. 
May be needed in some cases. 
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Table 1.5. Approaches to demonstrate accuracy according to ICH 
Drug substance 
Drug Product 
Impurities (quantitative) 
Application of the analytical procedure to a reference 
material 
Comparison of the results with those of a second, well 
characterized procedure. 
Application of the analytical procedure to Drug 
product synthetic mixtures of drug product 
components 
Spiking of analyte to drug product 
Comparison of the results with those of a second, well 
characterized procedure. 
Spiking of the impurity to drug substance 
or product 
Comparison of the results with those of a second well 
characterized procedure. 
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performed, as a qualitative verification of plausibility or an acceptable maximum 
difference should be defined. Spiking experiments for recovery investigations should be 
performed as closely to the authentic conditions as possible so that possible interferences 
between the analyte and matrix can be recognized. This ranges, for example, from the 
direct preparation of a drug product with various contents of active ingredient to which 
the whole analytical procedure is applied to the addition of a drug substance stock 
solution to a placebo solution. 
For the quantitation of the analyte, the same calibration mode as described in the 
final test procedure must be used. Again, statistical tests should be used carefully, 
especially with complex matrices and low concentrations of impurities. Alternatively, 
acceptable deviations from the theoretical recovery of 100% can be defined based on the 
application, experiences or general statistical considerations. 
Precision 
In addition to the ICH precision levels (Table 1.4), it is advisable to determine the 
system precision (injection repeatability) either by repeated determinations of the same 
test solution or firom double determinations of each test solution used for repeatability 
(Eq. 3). 
S''=\~t(\.-\2)' Eq.(3) 
Repeatability, also termed as intra-assay precision, refers to the precision obtained 
under the same operating conditions over a short interval of time by applying the whole 
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analytical procedure to the sample. Intermediate precision refers to within laboratory 
variations. The extent of investigations will depend on the intended use of the analytical 
procedure. Repeatability and intermediate precision can be calculated by an analysis of 
variances [236,237]. The difference between the precisions levels as well as their 
absolute magnitude indicate the robustness of the anal3^ical procedure. For the evaluation 
of the suitability (compatibility with specification limits) the intermediate precision can 
be regarded as the relevant parameter. From the standard deviation, the repeatability limit 
can be calculated (Eq. 4) which represents the maximum permitted difference between 
two repeated measurements. 
^ = ^«-i,o.95^^^'^*'2.8x5 Eq. (4) 
In this way, a straightforward verification is possible if the degree of scattering 
imder the actual conditions is comparable to the validation. By this parameter, the 
precision obtained during the validation studies using a larger number of data (thus 
increasing the reliability) is linked to the routine analyses without requiring a larger 
nimiber of experimental data. Reliable estimate of the standard deviation is required to 
calculate appropriate repeatability limits. 
Most statistical tests and calculations are based on the assumption that the 
experimental values are only influenced by random variability (i.e. that they are normally 
distributed). Data, which do not fulfill these assumptions (e.g. due to so called 'gross 
errors', weighing, dilution, or by problems with the instrument, etc.) will affect the 
results. Such values can be identified by statistical outlier tests (e.g. according to Dixon 
or Grubbs [236]) in order to eliminate them before performing further calculations. 
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Detection and quantitation limit 
Several approaches are given in the ICH guideline to determine the detection and 
quantitation limits (Table 1.6). Generally, they are based either on the analysis of blanks 
or on the scattering (variability) of the analytical signals in the low concentration range. 
Using the blank procedures, the corresponding calculation value is multiplied by the 
factors of 3.3 and 10 for the detection and quantitation limits, respectively. The 
calculation value may represent the signal of the blank, the standard deviation of the 
blank or of the intercept of a calibration line (corresponding to an extrapolated blank). In 
the latter tv/o cases, the analytical signal is transformed by the slope of the calibration 
line into a concentration [228]. Using the calibration line directly, the aforementioned 
factors (3.3 and 10) can be multiplied by the ratio from the residual standard deviation 
and the slope (corresponding to the standard error of slope) [228]. Limits calculated or 
extrapolated by these procedures should be verified by the analysis of samples in the 
corresponding concentration range [228]. This additional verification is already included 
in other procedures, which make direct use of the scattering around the calibration line by 
means of the 95% prediction interval around the regression line [238,239]. The 
quantitation limit can also be obtained directly from precision studies. For this approach. 
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Table 1.6. Approaches for determining the detection and quantitation limit [228]" 
Approach Detection limit Quantitation limit 
Visual evaluation Minimum level detectable Minimum level quantifiable 
Signal-to- noise 3: lor2 :1 10:1 
Standard deviation of the 3.3 X a/S lOxa/S 
response and the (a) slope (S) 
^Verification with suitable number of samples. 
*" Standard deviation of the blank, residual standard deviation of the calibration line, or standard deviation 
of the intercept. 
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decreasing analyte concentrations are analyzed repeatedly. The coefficient of variation 
(relative standard deviation) is plotted against the corresponding concentration. If a 
predefined limit for the coefficient of variation is exceeded (e.g. 10 or 20%), the 
corresponding concentration is established as the quantitation limit [240,241]. 
Study Proper and Statistical Analysis 
Daily standard curves are generated to determine the sample concentrations. All 
calibrators and quality control samples are analyzed in duplicate. Sample concentrations 
are based on single determination. The quality control sample sequence is carefully 
monitored for systematic errors. For each standard curve, the slope, intercept, variance, 
correlation coefficient and the interpolated calibrated concentration are reported. 
Acceptance of the assay results are determined by monitoring the quality control 
results. If the interpolated concentrations are v^ i^thin the control charts confidence limits, 
established during the method validation, the data are considered valid. Upon completing 
a study proper and accepting the analytical runs, the quality control results are 
incorporated into their respective data basis to update their confidence limits. 
Statistical calculations of the validation parameters and certain others of common 
interest 
Linear Calibration 
Linearity is often tested by using correlation coefficient, r. this quantity, whose 
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full title is "Product-moment Correlation Coefficient", is given by 
i:h-^){y.-y)] 
r = -
i:{^.-^i\L[y.-y)" 
\ii 
Where the points on the graph are {x^,y^), (xz.jVa) {^nV.) (^^'^^J' ^ ^ x 
and y are as usual, the mean value of x, and y, respectively. Value of r should be as: 
- l < r < + l . 
Least square Line 
The slope, b, and intercept, a, of the imweighted least square lines are found from. 
6 = -
YX{^.-x){y,-y)] 
/ _ \ 2 E(^'-^) 
a = y-bx 
Errors and confidence limits 
Random errors of the slope and intercept of the regression line involve the 
preliminary calculation of Sy/x, which is given by 
40 
ll/2 
Sy/x = 
Jl{y'-y>f 
n-2 
In this equation each y, value is measured signal value from the analytical 
instruments, while the corresponding y, is the value of y on the fitted straight line of the 
same value of x. After the determination of Sy/x, the standard deviation of the slope, Sb, 
and the standard deviation of the intercept, Sa can be determined from: 
S, 'ylx 
S(-,-?)' 
1/2 
^a - ^y/x 
E--
«Z(^.-^)' 
1/2 
These standard deviations can be used to estimate the confidence limit for the true 
slope and intercept values. The confidence limit for the slope are given by b + ts^ , where 
the value of "t" is chosen at the desired confidence level and with n-2 degree of freedom. 
Similarly, confidence limits for the intercept are given by a±tSi,. Standard 
deviation of S^^, can be calculated by using equation: 
-11/2 
s. = 
y/n 1 + - + 1 (yo-yf 
" b'Zi-,-^f 
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Where XQ and y^ are the value of single concentration and its instrument signal. 
In a typical analysis, the value of y^ might be obtained as the mean of m observations of 
a test sample, rather than as a single observation. 
ylx 
s„ = b 
1 , 1 , jyo-y) 
— 1 — I 
m n b^n-.-^r 
1/2 
Method of standard additions 
Matrix effects on the measured signal demand the use of standard additions. The 
concentration of the test sample, x^ is given by the intercept on the x-axis, which is 
clearly the ratio of the y-axis intercept and the slope of the calibration line as: 
a 
Limit of detection and sensitivity 
The lowest detectable instrument signal, jv ,^ is given by: 
y^=ys+KSs 
Where y^ and Sg are respectively, the blank signal and its standard deviation. After yj^ 
has been established, it can readily be converted into a mass or concentration limit of 
detection, c^ , as: 
^L=-
KS. 
42 
CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic and 
inorganic compounds. They can be prepared synthetically (from chemicals) or can be 
directly obtained or reconstituted from the natural sources/products. All the drugs having 
medicinal importance can be broadly divided into two classes. 
Chemical classification 
Here the drugs are classified according to their chemical structure and properties 
without taking the pharmacological actions vmder consideration, hi this class most of the 
drugs are having at least an organic substrate, the fiirther classification is done in the 
relevant manner. 
Pharmacological classification 
The drugs are classified according to their action on the organs (Viz., heart, brain, 
lymphatic system, respiratory system, endocrine system, central system, nervous system 
etc.) hence these drugs are named like antianginal, narcotics, soporifics, analgesics, 
diuretics and anaesthetics etc. Further classification of each group is done according to 
the therapeutic/pharmacological specificity Vvith the relevant organ. 
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Hepatoprotective Drugs 
The liver is subject to acute and potentially lethal injury by a number of 
substances, including phalloidm (the toxic constituent of the mushroom amanita 
phalloides), carbon tetrachloride, galactosamine, ethanol and other compounds. The 
effect of flavonoids on carbon tetrachloride induced toxicity in isolated rat hepatocytes 
has been studied by Perrisoud and Testa [242]. The ability to interfere with carbon tetra 
chloride-induced release of aspartate aminotransferase was tested on 55 flavonoid 
compounds. The more hydrophilic compounds were observed to inhibit the carbon tetra 
chloride-induced toxicity, whereas the more lipophilic derivatives actually potentiated the 
toxicity. In a number of countries, silybin and other flavonoids are widely utilized in the 
treatment of liver diseases [243]. 
Antianginals 
Angina pectoris is a heart ailment characterized by pressing chest pain that often 
radiates to the neck area and arms and shoulders (often towards left side). As a clinical 
entity William Heberden first characterized it under the name Pectoris Dolor in 1768, 
although its symptoms had been noted as early as 1632 [244-246], in the recent medical 
terminology it is referred as the symptom of ischaemic heart disease. For nearly a century 
following its first description, there was not much that could be done to relieve an angina 
patient of his agony: brandy, ether, chloroform, ammonia and other stimulants and 
depressants had been tried, but nothing seems to bring comfort. The breakthrough came 
in 1867 when T. Lander Bmnton, a British physician, reported his success with amyl 
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nitrite. In the authoritative but lively journal of medicine, the Lancet, he wrote, "On 
pouring from five to ten drops of amyl nitrite on a cloth and giving it to the patient to 
inhale, the pain completely disappeared and, generally did not return till its wonted time 
next night" [247]. And finally the continuous efforts of the medical researchers, they got 
succeeded in knowing the different reasons with this life-threatening ailment and its 
therapeutic solutions. 
Drugs used in angina pectoris are those that reduce cardiac work and myocardial 
need by (a) unloading the heart, (b) dilating the capacitance and resistance vessels, (c) 
dilating the coronary arteries and (d) blocking P-adrenoceptors. Anginal pain occurs 
when the coronary blood flow is insufficient to meet the hearts metabolic requirements. 
The drugs that either improve myocardial perfusion or reduce the metabolic demand, or 
both can covmteract it. Several antianginal drugs are available for the treatment of angina. 
These include (a) organic nitrates, (b) beta-adrenergic blockers, (c) calcium channel 
blockers, (d) potassium charmel activators, (e) antiplatelet drugs and (f) certain others like 
diazepam, oxyfedrine etc. 
This thesis deals with the quantitative analysis of silymarin, nifedipine, 
amiodarone hydrochloride and verapamil hydrochloride in pharmaceutical formulations. 
SUymarin 
Silymarin i.e. 3,5,7-trihydroxy,2-[3-(4-hydroxy-3-methoxy phenyI)-2-
(hydroxy-methyl)-I,4-benzodioxan-6-yl]-4-chromanone(structure I) is a free 
radical scavenger and a mixture of flavonolignans from medicinal plant Silybum 
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marianum, officially listed in Martindale [248] is used in supportive treatment of liver 
diseases of different etiology due to its hepatoprotective activity,[249-251] which is 
considered to involve antioxidative and the membrane stabilizing effects. The liver plays 
an important role in regulation of metabolism of plasma lipoproteins and liver injury is 
often reflected as a secondary dyslipoproteinaemia, which may lead to the development 
of atherosclerosis, particularly when associated with hypercholesterolaemia. [252] 
OH 0 
0 . ,CH20H 
OCH^ 
Structure I 
Nifedipine 
Nifedipine, chemically dimethyl-1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl) 
pyridine-3,5 dicarboxylate, is the prototype compound of dihydro pyridine class of 
calcium channel blockers with peripheral and coronary vasodilator properties. It reduces 
peripheral resistance, afterload and blood pressure. It is given by mouth in the 
management of hypertension and angina pectoris. In human, nifedipine is rapidly 
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metabolized by oxidative mechanism to dehydronifedipine wliich is further metabolized 
to more polar compoimds [253-256] and their structures are given below: 
HaCOOC^ ,C00CH3 
H3C 1 CH3 
H 
3HCOOC-
H ^ c ^ ^ r ^ 
^N02 
'COOCH3 
CH, 
H 
Nifedipine Dehydronifedipine 
3HCOOC-
H ^ C - ^ N ^ , 
'COOCH3 
CH, 
3HC 
H C2HCOOCV 
/ 
3HC 
HaC^  
I 
H 
-NO2 
'COOCH3 
^CH, 
Nitroso analogue of dehydronifedipine Nisoiidipine 
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Nifedipine is highly sensitive to photo-oxidation, changing in colour from yellow 
to brown upon exposure to light [257]. Nifedipine photodegration products have a little or 
no pharmacological activity [258,259]. Several studies in the past have been conducted to 
determine the photostability of nifedipine in solution and in the solid state, including 
photostability of pulverized nifedipine tablet powder [260-262]. 
Amiodarone hydrochloride 
Amiodarone hydrochloride,[2-n-butyl,3-(3,5-diiodo-4-diethylaminoethoxy 
benzoyl)-benzofuran] hydrochloride (structure II) is a potent class III 
antiarrhythmic drug [263]. It is used to treat ventricular and supraventricular 
arrhythmias, especially when they are resistant to other conventional 
antiarrhythmic drugs [264,265]. However, its use is sometimes complicated by 
serious adverse effects, including occasionally life threatening pulmonary 
fibrosis and hepatitis [266]. Therefore, its concentration in patients treated with 
therapeutic doses of the drug vary considerably and therapeutic drug monitoring 
of amiodarone hydrochloride may assist in individualizing the dosage regimen. 
In human, mono-N-desethylamiodarone is known as the major metabolite 
[267]. During long-term therapy, the plasma level of mono-N-
desethylamiodarone is comparable with that of amiodarone hydrochloride, and 
this metabolite may contribute to the therapeutic effect of amiodarone 
hydrochloride. 
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, ^ ^ ^ -O CH2 CH2- -N 
. / 
Ri 
\ 
R2 
o 
-c— 
0112(01^2)2^113 
Structure II 
Where Ri= R2 = C2 H5 (amiodarone), Ri = Hi, R2 = C2H5 (desythyl amiodarone), 
Ri = R2 = H (di-N-desythyl amiodarone). 
Verapamil hydrochloride 
Verapamil hydrochloride i.e. (±)-5-[(3,4-dimethoxyphenethyl) methyl amino]-2-
(3,4-dimethoxyphenyl)-2-isopropyl valeronitrile monohydrochloride (Structure III) is 
clinically a very useful member of the calcium channel blocker. It is used in the treatment 
of supraventricular arrhythmias, angina and hypertension [268-270]. The verapamil 
shows conduction through the atrioventricular node, and this slows the increased 
ventricular response rate that occurs in atrial fibrillation and flutter. A decrease in both 
coronary and peripheral vascular resistense together with a sparing effect on myocardial 
intracellular oxygen consumption, and the decrease in peripheral vascular resistance may 
explain the antihypertensive effect of verapamil [271-273]. 
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INTRODUCTION 
Silymarin i.e. 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxy phenyl)-2-
(hydroxy-methyl)-l,4-benzodioxan-6-yl]-4-chromanone is an important 
antihepatotoxic drug wiiich is obtained from the dried fruits of Silybum 
marianum and widely used for the treatment of hepatic disorders [1-4]. The 
drug is officially listed in Martindale The Extra Pharmacopoeia [5]. 
The assay procedure listed in the monograph of the Italian 
pharmacopoeia describes the UV-Vis spectrophotometric method [6] for 
determination of the drug in bulk and pharmaceutical formulations. Several 
other methods have been employed to determine silymarin in biological 
specimens and/or pharmaceutical formulations such as high performance 
liquid chromatography [7-21], thin layer chromatography [22-28], high 
performance thin layer chromatography [29], potentiometric titration [30], 
diffuse-reflectance fourier transform infrared spectroscopy [31] and UV 
spectrophotometry [32,33]. 
Spectrophotometry as a quantitative analytical tool still belongs to the 
most frequently used analytical techniques in pharmaceutical analysis. It 
provides practical and significant economic advantages over other methods. 
In the literature only few spectrophotometric methods have been reported. 
The drug content in pharmaceutical formulations was determined [34], based 
on the formation of coloured complex of the drug with 2, 4-dinitrophenyl 
hydrazine in the presence of tetramethyl amine hydroxide and quantitatively 
measured at 490 nm. Another spectrophotometric method has been developed 
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for the estimation of silymarin based on its reaction with diazotized sulfanilic 
acid in alkaline medium to form orange-red coloured chromogen, which 
absorbed maximally at 460 nm [35]. Reddy et al. [36] have reported two 
spectrophotometric methods for its determination. The first method was based 
on the oxidation of the drug by Fe (III) and estimating the reduced Fe (II) 
with 1,10-phenanthroline at 510 nm. The other method involved the formation 
of a blue complex on treatment with Folin-Ciocalteau reagent in the presence 
of NaOH and subsequent determination was done at 740 nm. These 
spectrophotometric methods are somewhat tedious and time consuming. 
Therefore, there is a need to develop a fast, low cost and selective method for 
routine analysis of silymarin in bulk and drug formulations. 
The extent of oxidation of organic substrate by potassium 
permanganate depends on the pH of the medium. The heptavalent manganese 
changes to Mn (VI) in alkaline medium while in neutral and acidic medium, 
the permanganate is further reduced forming ultimately Mn (II). This 
behaviour 'of permanganate has been exploited to develop a kinetic 
spectrophotometric method for assay of nifedipine in drug formulations [37]. 
In this chapter a fast, simple and sensitive kinetic spectrophotometric 
method for the assay of silymarin in bulk and pharmaceutical formulations is 
described. The method is based on the oxidation of silymarin by potassium 
permanganate at pH 7.0±0.2 and the course of the reaction was followed by 
measuring a decrease in absorbance at 530 nm. 
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EXPERIMENTAL 
Apparatus 
The absorbance was measured on a spectronic 20 D"^  spectrophotometer 
(Milton Roy, USA) with 1 cm glass cells. 
Reagents 
All chemicals used were of analytical or pharmaceutical grade. 
Potassium permanganate, 0.003M was freshly prepared by dissolving 47.41 
mg of potassium permanganate in 100 ml of doubly distilled water. The 
apparent purity of the potassium permanganate solution was checked 
titrimetrically [38]. 
Test solution 
Silymarin (1 mg ml'*) (Micro Labs, Bangalore, India) was prepared in 
methanol. 
Procedure for silymarin 
Kinetic spectropltotometric method for determination of silymarin 
Aliquots of 0.18-0.50 ml of silymarin standard test solution were 
pipetted into a series of 10 ml standard volumetric flasks. To each standard 
flask 1.6 ml of 0.003M potassium permanganate was added and then diluted 
to volume with doubly distilled water at 30±1°C. After mixing, reaction 
mixture was immediately transferred to spectrophotometric cell and the 
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decrease in absorbance was recorded as a function of time for 20 min at 530 
nm. The initial rate of the reaction (v) at different concentrations was 
obtained from the slope of the tangent to the absorbance-time curve. The 
calibration curve was constructed by plotting the logarithm of the initial rate 
of reaction (log v) versus logarithm of the concentration of the silymarin (log 
C). 
Procedure for determination of silymarin in pharmaceutical formulations 
An accurately weighed quantity of the mixed contents of five capsules 
or five powdered tablets, equivalent to 50 mg of the drug, was extracted into 
50 ml chloroform with shaking and the residue was filtered using Whatman 
No. 42 filter paper. The filtrate was evaporated to dryness and the residue was 
taken up with methanol and transferred to a 50 ml standard volumetric flask, 
diluting to volume. The assay was completed following the recommended 
procedure. 
RESULTS AND DISCUSSION 
The oxidation of organic compounds by permanganate is dependent 
upon the pH of the medium. During the course of the reaction the valence of 
manganese changes and intermediate ions have been suggested as 
participating oxidant. But the species having the main role as potential 
oxidant depends on the nature of the substrate and pH of the medium. The 
oxidation of silymarin by potassium permanganate at pH 7.0±0.2 was 
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followed spectrophotometrically by measuring the rate of change of 
absorbance at 530 nm. The absorbance-time curves are shown in Figs. 2.1. 
and 2.2., which are all sigmoid in nature throughout the entire range and 
therefore, the initial rates of reaction were determined from the slope of the 
initial tangent to the absorbance-time curves. The order with respect to 
permanganate was determined by studying the reaction at different initial 
concentrations of permanganate with fixed silymarin concentration. Keeping 
the silymarin concentration higher than that of the oxidant, the plot of initial 
rate [-d[A]/dt] against initial absorbance was linear passing through the origin 
suggested that the order of reaction with respect to permanganate at the start 
is one. The order with respect to silymarin was evaluated from the 
measurement of the rates at several concentrations of silymarin but at fixed 
concentration of KMn04 which was also found to be one. The first order 
dependence on both permanganate and silymarin in the initial stages leads to 
the simple rate expression: 
Rate = K [silymarin] [Mn04"] 
Silymarin is naturally occurring aryl chromanone (I) related to 
flavanone. The flavanones are 2,3-dihydro derivatives of flavones, which are 
readily interconvertible. Though the basic skeleton of flavanone and flavone 
is the same, the key which distinguishes one structural type from another is 
the oxidation level of the various carbons in the heterocyclic ring. The 
flavones are in a high state of oxidation where as flavanones are in low state 
of oxidation. The oxidation of flavanone with a variety of reagents such as 
selenium dioxide [39] or triphenyl methyl carbonium ion [40] has been 
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Time (min) 
Fig. 2.1. Absorbance-time curves: KMn04,4.8 xlO"^  M and silymarin 
(a) 3.731 X10-^  M; (b) 4.146 x 10"^  M; (c) 6.219 x 10"^ ; 
(d) 8.292 X 10-^  M; (e) 10.365 x 10"^  M 
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Time (min) 
Fig. 2.2. Absorbance-time curves: silymarin, 10.365 x 10"^  M and 
KMn04 (a) 3.00 x 10"* M; (b) 2.10 x 10"* M; (c) 1.50 x 10"* M; 
(d)9.00xlO-^M. 
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reported in which flavone is formed. In this study, the same mechanism seems 
to be involved. The oxidation of silymarin by permanganate takes place at pH 
7.0±02 leading to the formation of chromone (II). Thus, the dehydrogenation 
is effected by permanganate and consequently disproportionation between 
immediate oxidation states of manganese results in the formation of Mn02. 
However no precipitation of MnOa was observed under study time period. 
Therefore, the reaction mechanism is presented in scheme 2.1. 
Calibration graph and Statistical analysis 
Under the optimum experimental conditions, a calibration curve (Fig. 
2.3.) was constructed by plotting logarithm of initial rate of reaction (log v) 
versus logarithm of silymarin concentration (log C), which showed a linear 
relationship over silymarin concentration range of 18-50 \x.g ml''. The linear 
regression analysis using the method of least square was made to evaluate the 
slope, intercept and correlation coefficient. The linear regression equation and 
correlation coefficient are log v = 1.024 log C + 3.235 and r = 0.9997 which 
indicates an excellent linearity. The confidence limits for the slope of the line 
of regression and intercept were computed using the relation b±tSb and a±tSa 
[41], at 95% confidence level and found to be 1.024±3.96xl0"2 and 
3.235±I.67x10-', respectively. This indicated the high reproducibility of the 
proposed kinetic method. Linearity was also evaluated [42] from the relative 
standard deviation of the slope of the calibration line and found to be 1.215. 
The limit of detection was established using the equation [43,44]: 
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Fig. 2.3. Calibration curve for tlie determination of Silymarin. 
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Limit of detection = ^^ x 
2 n-2^ 
where n is the number of standard samples, t is the value of student's t for n-
2 degrees of freedom at 95% confidence level and So^  = variance. The 
variance and detection limit were calculated and found to be 1.100 x 10" ^g 
ml"' and 2.823 x 10"^  ^g ml"' respectively, which confirmed negligible 
scattering of experimental data points around the line of regression and good 
sensitivity of the method. 
The error (Sc) in the determination of a given concentration of 
silymarin (C) was established using the equation [45]: 
-|l/2 
Q _ So 
°""b" 
1+i^. <>'-^ >' 
n b^(ZC^-nC^) 
where y and C are average ordinate and abscissa values, respectively, for n 
standard samples. Fig. 2.4. shows the graph of Sc versus the concentration of 
silymarin. It is apparent from the graph that the error is reached minimum 
when the actual initial rate was equal to the average initial rate in the 
calibration graph. 
The minimum error of 1.123x10"^ fig ml"' was found in the 
determination of about 30 yig ml"' silymarin. The value of Sc also allows 
establishing the confidence limit at the selected level of significance for the 
determination of unknown concentrations by using the relation, C,±tSc The 
results are shown graphically (Fig. 2.5.) in the form of percent uncertaintyfi^. ,oo] 
on the concentration [46], at 95% and 99% confidence levels. This is 
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10""^  X1.30 
I 
Concentartion of silymarin (^g ml' ) 
Fig. 2.4. Error in the determination of tlie concentration of silymarin using 
statistical analysis of standard calibration data. 
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10-2 X4.5 
Concentration of slymarin (ng ml'^ ) 
Fig. 2.5. Variation of the confidence limit at (a) p= 0.05 and 
(b) p = 0.01 level of significance in the form of 
uncertainty percentage on the concentration of 
silymarin. 
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a useful way of expressing the confidence limits because the relative 
uncertainty can be estimated directly on the concentration over the full range 
of the concentration tested. 
The reproducibility was established for ten independent analyses of solution 
containing 0.40 mg silymarin. The analytical results obtained from the 
investigation are summarized in Table 2.1. The relative standard deviation 
and mean percent recovery were 0.873% and 100.33%, respectively and 
considered to be very satisfactory. The validity of the proposed kinetic 
method was checked by applying standard addition method and the results are 
reported in Table 2.2. 
The applicability of the proposed kinetic method for the determination 
of silymarin in dosage forms was examined by analyzing marketed products; 
the results were compared to those obtained by the reference method [35] and 
are summarized in Table 2.3. The performance of the proposed method was 
judged by calculating t- and F-values [47]. At 95% confidence judged level, 
the calculated t- and F-values do not exceed the theoretical values indicating 
no significant difference between the proposed kinetic method and the 
reference method. 
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Table 2.1. Precision test of the proposed kinetic method 
Sample 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Mean 
Initial rate of reaction 
(mol r' min'') 
11.455x10"^ 
11.508x10-^ 
11.376x10"^ 
11.350x10-^ 
11.561x10-^ 
11.534x10-2 
11.271x10-2 
11.402x10-2 
11.324x10-2 
11.297x10-2 
percent recovery = 100.33 % 
Relative standard deviation = •• 0 .833 % 
Amount found 
(Hg per 10ml) 
402.97 
404.79 
400.26 
399.37 
406.61 
405.70 
396.68 
401.17 
398.47 
397.57 
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Table 2.2. Determination of silyraarin in pharmaceutical formulations by standard 
addition method 
Preparation Amount taken 
(Hgml-') 
Amount added Total amount found 
(Hgml-') (Hgml-') 
Recovery RSD 
Silybin-70 
(tablet) 
Silvia-70 
(tablet) 
Limarm-70 
(capsule) 
Sivylar-70 
(capsule) 
Levalon-70 
(capsule) 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
20.03 
39.99 
20.03 
40.02 
20.02 
40.08 
20.03 
40.02 
20.04 
39.99 
100.16 
99.97 
100.18 
100.05 
100.11 
100.20 
100.18 
100.05 
100.20 
99.97 
0.354 
0.343 
0.471 
0.224 
0.585 
0.467 
0.578 
0.224 
0.685 
0.343 
' Three Independent analyses. 
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INTRODUCTION 
Nifedipine, chemically dimethyl-1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl) 
pyridine-3,5 dicarboxylate, is an important calcium cliannel blocker with peripheral 
and coronary vasodilator activity [1-5]. The drug is frequently used as 
antihypertensive and potent arterial vasodilator in the treatment of angina pectoris and 
various other cardiovascular disorders [6, 7]. The drug and its formulations are 
official in USP [8] and BP [9], which recommended HPLC and non-aqueous titration 
for its assay, respectively. 
The drug has been determined by a variety of analytical techniques such as 
HPLC [10-31], reversed phase HPLC [32-34], HPTLC [35], gas chromatography [36-
53], micellar electrokinetic chromatrography [54], electroanalytical methods [55-60], 
flow injection analysis [61], mass spectrometry [62] and UV spectrophotometry [63-
65]. 
The estimation of nifedipine alone was carried out using second-order 
derivative spectra [66] of the compound in 0.1 M HCl whereas first derivative spectra 
were utilized for its assay in combined dosage forms [67,68]. The methanolic solution 
of the drug reacts with 4-dimethylaminobenzaldehyde in H3PO4 resulting in the 
formation of yellow coloured product, which forms a basis for its determination at 
380 nm [69]. Two spectrophotometric methods have been recommended, one is based 
on the formation of blue coloured complex with Folin Ciocalteau reagent [70] and 
second method involves the charge transfer complex formation with chloranil [71]. A 
kinetic spectrophotometric method has also been described based on oxidation of drug 
with KMn04 at neutral pH [72]. The other two spectrophotometric methods were 
developed which involved the reduction of nifedipine with Zn/NHtCl and Zn/HCl to 
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hydoxylamino derivative and primary aromatic amino derivative, respectively 
[73,74]. The hydoxylamino derivative was reacted with 4-(methylamino) phenol and 
potassium dichromate to give a chromophore, which absorbed maximally at 525 nm. 
Thp aromatic amino derivative formed schiffs base with 3,4,5-
trimethoxybenzaldehyde and subsequently determined at 365 nm. So far, no 
extractive spectrophotometric method for the assay of nifedipine in pharmaceutical 
formulations was reported. 
In this chapter, four new extractive spectrophotometric methods for the 
determination of nifedipine have been discussed. The methods are based on the 
reduction of nitro group of nifedipine by Zn/HCl into primary amino derivative which 
forms chloroform extractable ion pair complexes with bromocresol green (BCG), 
bromophenol blue (BPB), bromothymol blue (BTB) and eriochrome black T (EBT). 
EXPERIMENTAL 
Apparatus 
A Spectronic 20D* spectrophotometer (Milton Roy, U.S.A.) was used to 
measure the absorbance. 
An Elico model Li-10 pH meter was used for pH measurements. 
Reagents and standards 
Preparation of amino derivative of the nifedipine 
A 0.05 % solution of reduced nifedipine was prepared by treating a mixture of 
12.5 mg of pure nifedipine (J.B. Chemicals and Phannaceuticals Ltd., Mumbai 
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India), dissolved in 3 ml ethanol, 1.8 ml of 5M HCl for BTB (2.5 ml for BCG and 
BPB; 3.0 ml for EBT required for ion pair formation) and 3.0 g of Zn dust. The 
content was allowed to stand for 20 min at 25 ± 1°C. The solution was then filtered 
through a Whatmann No. 42 filter paper, the residue was washed with two 5 ml 
portions of doubly distilled water. The filtrate and washings were diluted to volume in 
a 25 ml standard volumetric flask with doubly distilled water. 
0.025 % solutions of bromocresol green (S.d. fine Chem Limited, India), 
bromophenol blue (S.d. fine Chem Limited, India), bromothymol blue (S.d. fine 
Chem Limited, India) and eriochrome black T (Fluka Chemie A G, Germany) were 
prepared by dissolving 25 mg of each dyestuff in 100 ml standard volumetric flask 
and diluting to volume with doubly distilled water. 
Procedure of calibration curve 
Into a series of 50 ml separating funnel 7 ml of BCG (BPB, BTB or ETB) 
followed by an appropriate volume of 0.05 % reduced nifedipine (0.10-0.65 ml for 
BCG; 0.08-0.75 ml for BPB; 0.13-0.66 ml for BTB and 0.09-0.45 ml for EBT) were 
placed and mixed well. Then 10 ml of chloroform was added to each funnel. The 
contents were shaken for 2 min and allowed to separate the two layers. The 
absorbance of the organic layer was measured at 415 nm for BCG, BPB, BTB ion-
pair complexes and 520 nm for EBT ion-pair complex against a reagent blank 
prepared similarly in each case. The calibration curve was constructed, in each case, 
by considering the absorbance measured at seven concentration levels of nifedipine. 
The amount of the drug was computed either from calibration curve or from 
regression equation. The colour of the complexes were stable for at least 2 hours. 
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Procedure for the assay of drug in dosage forms 
An amount of the tablet or capsule equivalent to 12.5 mg of nifedipine was 
weighed accurately, and extracted into 25 ml chloroform with shaking. Filtration 
through a Whatmann No. 42 filter paper was performed. The filtrate was evaporated 
to dryness under vacuum and the residue was dissolved in 3 ml ethanol and converted 
into amino derivative following the procedure given under the head "preparation of 
amino derivative of the nifedipine" and then subjected to the recommended procedure 
for the determination. 
RESULTS AND DISCUSSION 
Nifedipine contains -NO2 group, which is reduced to amino derivative by zinc 
dust and HCl. In the present study, the reduced nifedipine possessing primary 
aromatic amino group is protonated in acidic medium, which forms ion-pair 
complexes with each of the acid dyes such as BCG, BPB, BTB and EBT. The ion-
associated complexes are quantitatively extracted with chloroform. The absorption 
spectra are shown in Fig. 3.1. which revealed that the ion-pair complexes with BCG 
(BTB or BPB) and EBT absorbed maximally at 415 and 520 nm, respectively. The 
reagent blanks prepared under similar conditions showed no absorption. 
Composition and formation constant of ion-pair complexes 
The stoichiometry of ion-pair complexes of the reduced drug with each of the 
dyestuffs was established following the method of continuous variations [75]. The 
results (Figs. 3.2., 3.3., 3.4. and 3.5.) indicated that the molar ratio of the drug to 
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Fig. 3.1. Absorption spectra: (a) Amino derivative of nifedipine-BCG 
complex; (b) Amino derivative of nifedipine-BPB complex; (c) amino 
derivative of nifedipiae-BTB complex; (d) amino derivative of 
nifedipine-EBT complex. 
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Fig. 3.2. Job's plot for drug-dye (1.443 x 10"^  M) system: 
BCG. 
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Fig. 3.3. Job's plot for drug-dye (1.443 x 10"^  M) system: 
BPB. 
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EBT. 
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dyestuff in each compound is 1:1. The formation constants [76,77] were also 
calculated and found to be 2.91 x 10^ 3.32 x 10^ 5.82 x 10^  and 5.54 x 10^  for 
complexes with BCG, BPB, BTB and EBT, respectively. 
On the basis of literature background and our experimental findings, the 
reaction mechanism is proposed and given in scheme 3.1. 
Optimization of the reaction conditions 
The optimum conditions for quantitative estimation of the drug were 
established via a number of preliminary experiments. 
Effect of concentration of hydrochloric acid 
The influence of the concentration of HCl on the reduction of the nifedipine 
and subsequent ion-pair formation of amino derivative of the drug with various 
dyestuffs has been studied. The results are shown in Figs. 3.6., 3.7., 3.8. and 3.9. It is 
apparent from figure that the absorbance of ion-pair complexes with BCG (or BPB), 
BTB and EBT was found to be constant when the reduction was done in the range of 
0.47-0.53 M, 0.34-0.40 M and 0.56-0.64 M HCl, respectively. For the most efficient 
extraction of ion-pair with chloroform the optimum value was fixed at 0.50 M, 0.36 
M and 0.60 M HCl for ion-pair formation with BCG (or BPB), BTB and EBT, 
respectively. 
Effect of dye concentration 
The effect of dye concentration on the intensity of the colour at the selected 
wavelength and constant nifedipine concentration was critically examined using 
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Fig. 3.6. Effect of the concentration of HCI: 31 ^g ml"' drug + 7 ml of 0.025% 
BCG. 
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Fig. 3.9. Effect of the concentration of HCI: 22.5 ^g ml"' drug + 7 ml of 0.025% 
EBT. 
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different milliliters of the reagent (0.025 %). The results indicated (Figs. 3.10., 3.11., 
3.12. and 3.13) that the maximum absorbance, in each case, was found with 6.0 ml of 
the reagent, beyond which absorbance become constant. Therefore, 7.0 ml of each 
dyestuff was used for ion-pair formation throughout the experiment. 
Choice of organic solvent 
A number of organic solvents such as chloroform, carbon tetrachloride, 
dichloromethane, benzene and toluene were examined for extraction of the ion-pair 
complex in order to provide an applicable extraction procedure. Chloroform was 
preferred for its selective extraction of ion-pair complex from the aqueous solution. 
Shaking time of 0.5-4.0 min. provided a constant absorbance and hence, 2.0 min was 
used as an optimum shaking time throughout the experiment. The ion-pair complexes 
were quantitatively recovered in one extraction only and were also stable for at least 2 
hours. 
Effect of excipients 
A systematic study of the effect of excipients was performed, following the 
proposed procedures for a 10 ml sample system., by adding a known amount of 
excipients to the fixed nifedipine concentration (22.5 \i.% ml"'). The results revealed 
the fact that no significant interference was observed from the excipients such as 
glucose, fructose, sucrose, lactose and starch commonly present in pharmaceutical 
formulations. However, the drug content from the powdered tablets or capsules were 
extracted into chloroform which completely eliminates the common excipients found 
in drug formulations. 
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Fig. 3.13. Influence of the volume of 0.025% dye: EBT. 
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Analytical data 
Calibration graphs (Figs. 3.14., 3.15., 3.16. and 3.17.) were constructed, by 
measuring the absorbance at seven concentration levels, which showed linear 
response of absorbance in relation to concentration of nifedipine over the range of 
5.0-32.5, 4.0-37.5, 6.5-33.0 and 4.5-22.5 |ag ml'' for BCG, BPB, BTB and EBT 
methods, respectively. Regression analysis of calibration graphs indicated linear 
relationship with negligible intercepts. Table 3.1. summarizes the analytical 
parameters, molar absorptivities and the results of statistical analysis of the 
experimental data: regression equations computed from calibration graphs along with 
standard deviation of slope (Sb) and intercept (Sa), confidence interval of slope (tSb) 
and intercept (tSa) on the ordinate. The detection limits [78,79] were found to be 1.06, 
0.09, 0.11 and 0.20 [ig ml"' for BCG, BPB, BTB and EBT methods, respectively. The 
small value of variance, further, suggested least scatter of experimental data points 
around the line of regression. 
The repeatability of the proposed procedures was checked by performing ten 
replicate determinations of nifedipine at concentration levels of 20 and 30 fig ml'' 
with BCG (or EBT) and BPB (or BTB), respectively. The relative standard deviations 
(RSD %) and recoveries were found to vary over the range of 0.66-0.82 % and 99.8-
100.7 %, respectively. 
The accuracy of proposed methods was demonstrated by recovery 
experiments, which were carried out by adding a fixed amount of pure drug to the 
preanalyzed dosage forms. The analytical results obtained are summarized in Table 
3.2. 
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Fig. 3.14. Calibration curve for determination of nifedipine witli BCG. 
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u 
115 
Da 
in T t 
^ 
o y—t 
X 
c?. 
^ t^  
o 
I—1 
X 
•—« 
cs 
+ 
T 
o 
X 
o 
o 
r-4 
fS 
I  
< 
T 
o 
•—1 
X 
o 
o 
cs 
tN 
7 
o 
I—1 
X 
o 
oo 
• * . 
*-H 
1 
o 
J—i 
X 
•o 
o 
so 
c^  
% 
X 
f-H 
CN 
CN 
1 
o »-H 
X 
o 
q 
ri 
T 
o 
t—l 
X 00 
ts 00 
ri 
OS 
o\ Ov 
OS 
d 
*o 
O 
f-H 
X 
oo 
"Tj 
m 
o 
ts 
d 
oo VO 
d 
'^  rJ d 
rH 
o 
t3 
o 
cu 
o 
.ci 
o 
u 
• • ^ 
."' 
u 
M 
« 
u 
"w 
u 
1 
o 
X 
m 
oo 
o 
c 
O 
m 
>/1 O 
q 5; 
•* <n *d 
>ri 
U 
X 
q 
c^  
1 
>n 
vd 
O 
X 
VO 
CN 
vi 
X 
o 
q 
*-H 
II 
< 
o 
X 
o 
o 
+ T o 
I—< 
X 
o 
cs 
II 
< 
U 
X 
0 0 
-Si E 
2 
ca 
CL, 
6 c 
£ 
*1 
1 
o X 
o 
t^  
q 
^ 
T 1 
o «-^  X 
o 
o 
t^  
in 
T' 
b f—1 
X 
>n 
vo 
•*. 
f—< 
r< 1 
o 
*-H 
X in 
»—» "O 
-H 
I 
o 
»—( X 
o 
q 
f*i 
tn 
1 
O 
*—t 
X 
m 9-^ 
t>_ 
f^ 
o\ 0\ 
OS 
OS 
d 
1 
O 
f-H 
X OS 
»—; in 
0 0 
o ^ 
T 
o 
T 
o 
t 
o 
»-H f -H »—< i -H O <"* 
o 
CN 
X 
o 
o 
0 0 i X o o I X CN o o o o X 00 OS o 
m CO Os 
. o 
CN 0 0 
O <7\ 
o 
X 
o 
t—) 
11 
< 
T 
o t-H 
X 
o 
o f-H 
• * 
T 
o 
X 
o 
o 
ri 
00 
T 
o 
X 
n t — < 
»-H 
CN 
V 
o 
•-H 
X OS 
•<3-
SO 
<—< 
"? o r—t 
X 
o 
o 
• * 
T 
o t—( 
X 00 
CS 
q 
i-H 
OS 
o C3s 
OS 
d 
ws 
1 
o r—( 
X 
o 
o 
r-^  
so 
q 
i-H 
CN 
OO 
d 
oo 
q 
d 
o 
-"^  T 
"E 
60 
3 
.*J 
_s 
s cd 
"*"• 
» 
u 
u 
23 
' 1 
o 
E 
J, 
>, 
'> 
Q. 
u. 
O 
JD 
CO 
O 
c 
c 
• ^ 
cr 
u 
g 
'w 
t3) 
Ui 
u. 1 
—^s 
ca 
o. 
u 
o 
vl5 00 ' i i 
O 
c u 
'o 
u 
o 
o 
c 
u 
Ui 
u 
o 
o 
^ 
§ 
> u 
E ^J ^ 
:= 2 
u u 
c 
.3 
> 
c 
o 
H -s 
e 
> 
u 
c 
C3 
4 2 
a) 
.2 o s 
s is 
8 S "a 
o p^ o 
o in Z, 
O o o 
r; u. p . 
g c •« 
r f"" ^ U J •£ 
•° t; •« 
+ o ° « 
ca w ^ u 
II "3 S U 
^ 5 i3 § o -is -
4-» r* C ^ 
* j . = — O 
O 
u 
D . sis 
^ 'S ^ 
^ O "^  P 
116 
-a o 
.a 
a> 
B 
a 
r: 
a 
d o 
1-1 ja 
"3 
S 
u 
s 
u 
s 
u 
R 
B 
-a 
e 
o 
c 
o 
'(^  
a 
u 
*-
Q 
H 
CO vP 
O vP 
a I. 
60 
I 
< 3 
§ 
ca 
CS 
o 
en 
o 
d 
c^ 
c> 
d 
CO 
d 
d 
o 
d 
CS 
d 
en 
d 
d 
5 
d 
d 
en 
d 
cs 
V5 
d 
o 
rn d 
es 
d 
d 
ON 
d 
CS 
d 
C<1 
d 
o 
d 
CS 
d 
o 
d 
o> 
J J 
l -
o 
K; 
nt 
•o L H 
o 
;^  
CS 
o 
0 0 
CS 
o 
o 
o 
m 
•* 
o 
CO 
o 
o 
m 
o 
o 
• * 
o 
CS 
o 
00 
CM 
o 
C S 
CO 
o 
•—< 
CO 
o 
•—* 
o 
c^ 
CO 
o 
o 
o 
^ q d 
o 
'"' 
^ 
o 
o\ 
o\ 
<^  o 
d 
o 
'^ 
• * 
q d 
o 
c^ 
q d 
o 
i - ^ 
CS 
o 
d 
o 
*"• 
•^  C3S
O N 
o> 
I—C 
q d 
o 
T t 
q d 
o 
'^  
^ 
ON 
OS 
CJN 
o\ 
o 
d 
o 
'"' 
o 
d 
o 
rr> 
q d 
o 
'"' 
T ( -
o\ 
OS 
OS 
t OS 
OS 
cr\ 
»-H 
q d 
o 
• < * 
o 
d 
o 1—I 
•* 
o 
d 
o 
CS 
o 
d 
o 
'"' 
OS 
crs 
OS 
0 \ 
f<i 
o 
d 
o 
*—1 
C<1 
o 
d 
o 
*—< 
TT 
OS 
OS 
OS 
»—< 
o 
d 
o 
o 
o o 
o 
o 
o 
i n 
OS 
0 \ 
C7\ 
0 ^ 
CJs 
m 
o o o 
CO 
o 
o 
o 
CO 
T—« 
o o 
»—< 
CS 
CS 
o o 
O S 
O N 
CJN 0\ 
o 
o o 
f-H 
CJN 
o o o 
o 
o o 
o o 
C?N 
CS 
o o o 
CO 
o o 
r—< 
o 
o o 
o o 
^ i n --I 
CO 
3 
03 U 
c4 
•a 
< 
o o 
— in « 
CO 
3 
60 
C 
1) 
•a c u 
D. O 
•a c 
03 
u 
03 
u 
117 
The percent relative standard deviations (0.12-0.62 %) can be considered to be very 
satisfactory. 
The performance of the proposed methods was compared with that of other 
existing UV-Visible spectrophotometric methods (Table 3.3.). It is evident from the 
table that the proposed methods are more sensitive then the other reported method due 
to their higher molar absorptivities and present better accuracy with narrow linear 
dynamic range. The methods are found to be simple and can compete with other 
existing spectrophotometric methods in determining drug In lower concentrations. 
The order of performance of the proposed methods is EB'I>BCG>BTB>BPB. 
The proposed methods have been successfully applied to the determination of 
nifedipine in commercial tablets and capsules purchased locally. The results (Table 
3.4.) obtained by the proposed methods were compared by BP method [9]. The 
calculated student's t-value and F-values did not exceed the theoretical ones at 95 % 
confidence level. Therefore, there is no significant difference between the proposed 
methods and BP method. 
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INTRODUCTION 
Amiodarone hydrochloride, 2-butyl, 3-benzofliranyl 4-[2-diethyl amino 
ethoxy]-3-5-diiodophenyl methanone hydrochloride is an important 
antiarrhythmic drug [1-3], used only in the treatment of documented life-
threatening recurrent ventricular dysrhythmias. It undergoes hepatic 
metabolism to produce a major metabolite, desythyl amiodarone, which can 
approach the concentrations of the parent drug during chronic therapy. The 
molecular formulae of amiodarone and its metabolites are given as: 
< ^ ^ 
O 
II 
-c- -O CHz CH, N 
/ ' ^ 
\ 
R2 
^0 CH2(CH2)2CH3 -j 
Where Ri= R2= C2 H5 (amiodarone) 
Ri = HI , R2 = C2 H5 (desythyl amiodarone) 
R] = R2 = H (di- N- desythyl amiodarone) 
British Pharmacopoeia [4] describes potentiometric titration and 
spectrophotometric method for the assay of amiodarone hydrochloride in pure 
form and pharmaceutical formulations, respectively. The different analytical 
techniques that have been reported for the determination of cited drug in 
biological fluids and pharmaceutical formulations include high performance 
liquid chromatography [5-11], high performance thin layer chromatography 
[12], liquid chromatography [13-14], infrared spectroscopy [15], fluorimetry 
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[16] and electrochemical methods [17-19]. In the literature only few 
spectrophotometric methods have been reported. Sastry et al. [20] have 
described two spectrophotometic methods for the determination of 
amiodarone hydrochloride based on its reaction with a known excess of iodine 
or ammonium molybdate and estimating the unreacted iodine or reduced 
ammonium molybdate with metol - sulfanilic acid or potassium thiocyanate. 
The reaction [21] between amiodarone and citric acid-acetic anhydride 
reagent yielded an intensely blue coloured product and absorbance was 
measured at 580 nm. The drug content in pharmaceutical formulations was 
also determined spectrophotometrically [22] using the charge transfer 
complexation reaction of drug with chloranil and iodine at 500 and 290 nm, 
respectively. The extractive spectrophotometric methods [23] have also been 
utilized based on extractable ion-pair complexes of the drug with tropaeolin 
00, tropaeolin 000 and wool fast blue at 420, 480 and 580 nm, respectively. 
A survey of literature reveals that the existing spectrophotometric 
methods [20-23] dealing with the estimation of amiodarone in drug 
formulations suffer from some disadvantages such as narrow linear dynamic 
range requires heating or extraction and long analysis time. Therefore, the 
development of fast, simple, sensitive, low-cost and selective methods is the 
need of the day especially for a routine quality control analysis of 
pharmaceutical products containing amiodarone hydrochloride. 
The charge transfer reaction of certain n- acceptors such as p-
chloranilic acid [24-26] and 2,3-dichloro5,6-dicyanol,4-benzoquinone [27-
31 ] has been successfully utilized in pharmaceutical analysis. 
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This chapter describes two rapid and simple visible spectrophotometric 
methods for the determination of amiodarone hydrochloride by exploiting its 
basic nature and electron donating property. The methods (A and B) are based 
on charge transfer complexation reaction of amiodrone base with p-chloranilic 
acid and 2,3-dichloro5,6-dicyanol,4-benzoquinone(DDQ) in dioxane-dichloro 
methane and acetonitrile media, respectively. The proposed methods were 
validated statistically. 
EXPERIMENTAL 
Apparatus 
Spectral runs and absorbances were recorded on a spectronic 20 D"^  
spectrophotometer (Milton Roy Company, USA) with 1 cm matched glass 
cells. 
Reagents and Standards 
Amiodarone hydrochloride was kindly provided by Troikaa 
Pharmaceuticals Ltd. India and was used as received. Commercial dosage 
forms of amiodarone hydrochloride such as Aldarone (Zydus Alidac), 
Amiodar (Cardicare), Duron (Samarth Pharma) and Eurythmic (Troikaa) were 
purchased from local market. 
All other reagents used were of analytical grade. Solutions of p-
chloranilic acid (0.08%; Fluka, Switzerland) and DDQ (0.08%; Fluka, 
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Switzerland) were prepared in dioxane and acetonitrile, respectively. An 
aqueous solution of sodium carbonate (0.5M, Merck, India) was prepared in 
doubly distilled water. 
The standard solutions of amiodarone base (2.0 mg ml'' and 0.5 mg 
mr') were prepared in dichloromethane. 
Recommended Procedures 
Preparation of amiodarone base: 
To prepare amiodarone base solution, 25.0 ml of 0.2% (2.0 mg ml') 
amiodarone hydrochloride and 50.0 ml of 0.5 M NaiCOs solutions were 
transferred into a 250 ml separating funnel. The contents of the separating 
funnel were mixed well and shaken for 1 min. The two layers were allowed to 
separate. The dichloromethane layer was dried over anhydrous sodium sulfate 
and diluted to 25 ml with dichloromethane. A working standard solution of 
amiodarone base (0.05%) was prepared on further dilution. 
Method A: 
Aliquots of 0.2%. amiodarone base solution (0.025 - 0.90 ml) were 
pipetted into a series of 5.0 ml standard volumetric flasks. 1.5 ml of 0.08% p-
chloranilic acid was added to each flask and diluted to volume with 
dichloromethane. The coloured product formed immediately and remained 
stable for 1.5 h. The absorbance was measured within the stability period (2-
90 min) after dilution at 535 nm against the reagent blank prepared 
simultaneously. 
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Method B: 
Aliquots of 0.05% amiodarone base corresponding to 10 - 325 p-g were 
pipetted into a series of 5.0 ml standard volumetric flasks. To each flask, 1.5 
ml of 0.08% DDQ was added and completed to volume with acetonitrile. The 
absorbance was measured at 570 nm within the stability period of 3 - 40 min 
against the reagent blank prepared similarly, omitting the drug. 
Procedure for determination of commercial dosage forms 
Ten tablets were powdered, mixed thoroughly and weighed accurately 
to an amount equivalent to 200 mg of amiodarone hydrochloride. It was 
stirred well with dichloromethane and filtered through Whatmann No. 42 
filter paper. The residue was washed with dichloromethane for complete 
recovery of the drug. The filtrate and washings were diluted to volume in a 
100 ml standard flask. The amiodrone hydrochloride solution was converted 
into amiodrone base following the recommended procedure given under the 
head "preparation of amiodarone base solution". It was further diluted 
according to the need and then analyzed following the recommended 
procedures. 
RESULTS AND DISCUSSION 
The spectrum of p-chloranilic acid in the dioxan-dichloromethane 
mixture exhibits an absorption band at 440 nm. The addition of amiodarone 
base to this solution causes an immediate shift with a new characteristic band 
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at 535 nm (Fig. 4.1.). The band may be attributed to the formation of 
p-chloranilic acid radical anion. The p-chloranilic acid in dioxane-
dicholoromethane medium exists in unionized form and acts as n -acceptor in 
a similar marmer to quinines [32]. Some hydrochloride salts of amines do not 
possess a lone pair of electrons and hence, unable to react with a or 71-
acceptors. Similarly, amiodarone hydrochloride does not react with p-
chloranilic acid owing to non-availability of n-electrons. In order to establish 
the assay procedure for amiodarone hydrochloride, it is necessary to convert 
amiodarone hydrochloride solution into amiodarone base solution. Due to the 
same reason, amiodarone hydrochloride was dissolved in dichloromethane 
and shaken with a 0.5 M aqueous sodium carbonate solution, resulting in the 
formation of amiodarone base in the dichloromethane layer. The addition of 
p-chloranilic acid to amiodarone base (n-donor) results in the formation of a 
charge transfer complex of the n -T: type. This compound is believed to be an 
intermediate molecular association complex, which dissociates in dioxane-
dichloromethane solvent, producing p-chloranilic acid radical anion. The 
mole ratio method [33] has been applied to establish the stoichiometric ratio 
of amiodarone base to p-chloranilic acid and was found to be 1:1 (Fig. 4.2.). 
This indicated the presence of one n-donating center in the amiodarone base 
for charge transfer complexation reaction. On the basis of literature 
background search and our experimental findings, a reaction mechanism is 
proposed (Scheme 4.1.). 
DDQ is TT-acceptor, which reacts instantaneously with basic 
nitrogenous compounds to form charge transfer complexes of the n-7r type. 
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350 400 450 500 550 
Wavelength (nm) 
600 650 700 
Fig. 4.1. Absorption spectra of (a) 2.30 X 10'^  M p-ciiloranilic acid 
(b) 0.36 |ig ml'* amiodarone with 1.15 X 10"^  M p-chloranilic acid 
in dioxan- dichloromethane. 
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Fig. 4.2. Molar ratio plot for amiodarone - p - chloranilic acid complex; 
amiodarone concentration, 2.933 X 10"^  M. 
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The absorption spectrum of DDQ in acetonitrile shows a characteristic band 
peaking at 350 nm. The addition of amiodarone base to this solution causes an 
immediate change in the absorption spectrum with new characteristics bands 
peaking at 435, 540 and 570 nm (Fig 4.3.)- These bands may be attributed to 
the formation of DDQ radical anions, which probably resulted through the 
dissociation of the donor-acceptor complex in a highly polar solvent like 
acetonitrile. In order to avoid the maximum interference from the reagent 
blank, the absorbance measurements were made at 570 nm. The mole ratio 
method (Fig. 4.4.) suggested a donor to acceptor ratio of 1:1, confirming the 
presence of one n-donating center in the amiodarone base molecule. The 
reaction sequence for the formation of DDQ radical anion is shown in Scheme 
4.2. 
The molar absorptivities and association constants for amiodarone-p-
chloranilic acid and amiodarone - DDQ reaction products were calculated using 
Ross and Labes equation [34]. 
[A][D] 1 _ j _ 1 ^ 1 
[A] + [D] ^ A;,^° KS;, [A] + [D] Ej, 
where [A] and [D] are the molar concentrations of the acceptor and donor, 
respectively, A / ' ^ and sx are the absorbance and molar absorptivity of the 
complex at the specified m^ax- K is the association constant of the complex. 
The values of association constant (K) and molar absorptivity (ex) were 
obtained from the plot of 1 against [A] [D] i 
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n 1 1 1 I T — ^ — I 1 r 
300 340 380 420 460 500 540 580 620 660 700 
Wavelenth (nm) 
Fig. 4.3. Absorption spectra of (a) 8.81 X10"* M DDQ in acetonitrile 
(b) 65 x^g ral"^ amiodarone with 1.06 X 10"^  M DDQ in 
acetonitrile. 
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2.00 
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Fig. 4.4. Molar ratio plot for amiodarone -DDQ complex; amiodarone 
concentration, 2.933 X 10"^  M, 
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(Figs. 4.5. and 4.6.). The free energy was also computed. The results are given 
in Table 4.1. 
Optimization of variables ' 
The spectrophotometric properties of the coloured species formed with 
p-chloranilic acid and DDQ as well as the different parameters affecting the 
colour development were extensively studied. The optimum conditions for the 
assay procedures (method A and B) have been established by studying the 
reactions as a function of the concentration of reagent, nature of the solvent 
and the stability of the coloured species. 
Effect of the concentration of p-chloranilic acid 
For method A, the effect of the volume of 0.08% p-chloranilic acid was 
studied over the range of 0.2 -1,5 ml in a solution containing 360 [a,g ml"' 
amiodarone. The results (Fig. 4.7) revealed the fact that 1.0 ml of p-
chloranilic acid was required to achieve the maximum intensity of the colour. 
Therefore, 1.5 ml was used as an optimum value and maintained throughout 
the experiment. The reaction gets stabilized within 2.0 min of mixing at room 
temperature and absorbance remained constant for a further 90 min. 
Effect of the concentration of DDQ 
For method B, the only effective variable is the concentration of DDQ. 
To study the influence of the volume of 0.08% DDQ, an aliquot of drug 
containing 300 |ag was pipetted into a series of 5.0 ml standard volumetric 
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1 0 ' ^ X 1 .1 
1.7 1.8 1.9 2.0 2.1 2.2 2.3 xlO^ 
lA ] + [Z? ] 
Fig. 4.5. Plot of ^ _ ^ _ ^ versus r .-, r J-. x — ^ r for 1:1 complex 
of amiodarone - p- chloranilic acid. 
AD 
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10"'^x3.9 
2.3 x10^ 
[A]+[D] 
Fig. 4.6. Plot of 
amiodarone -DDQ. 
[A][D] 1 
versus , • . • " • , , x [^ ] + [D] ,^ AD for 1:1 complex of 
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Table 4.1. Association constant, K; molar absorptivity, ej. from the Ross and 
Labes plots for the complex and calculated free energy, AG 
Parameter Amiodarone -p-chloranilic acid Amiodarone - DDQ complex 
complex 
3.855 X 10^  
7.502 X lO' 
-15.251 
K(lmor') 
E X (1 mol'' cm"') 
AG (KJ mor') 
1.107X10^ 
1.421 X 10^  
-17. 953 
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0.2 0.4 0.6 0.8 
Volume of p-chloranillic acid (ml) 
Fig. 4.7. Influence of the volume of 0.08% p-chloranilic acid. 
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flasks followed by varying volumes of 0.08% DDQ (0.1-1.5 ml) and diluted 
to volume with acetonitrile. Fig. 4.8 shows that the highest absorbance was 
obtained with 1.0 ml of 0.08% DDQ. Further addition of DDQ caused no 
change in the absorbance and hence, 1.5 ml was selected as an optimum 
volume for all determinations. The intensity of the colour formed on mixing 
the reagent reached maximum within 3 min. and was stable up to 35 min. at 
room temperature. Therefore, it is recommended that the absorbance be 
measured within this time period. 
Analytical data 
Table 4.2. summarizes the analytical parameters such as Beer's law 
limit, calibration equations obtained by least square treatment of calibration 
data, coefficient of correlation, variance, confidence limit for slope and 
intercept . The high value of correlation coefficient suggested the excellent 
linearity of both the calibration graphs (Figs 4.9. and 4.10.). The values of 
confidence limit at 95% confidence level for slope and intercept of the 
regression lines pointed towards high reproducibility of the proposed 
methods. Test of significance of the intercept of the regression lines showed 
that the experimental intercepts, a, for method A and B do not differ 
significantly from the theoretical value of zero. For this justification, a 
simplified method was used to calculate the quantity from the relation t = a/Sa, 
[35] and its comparison with the tabulated data from the t-distribution. The t-
value for method A and B were found to be 0.056 and 0.596, respectively, 
which did not exceed the tabulated t- value ( t = 2.365, when v = 7 ) at 95%) 
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Fig. 4.8. Influence of the volume of 0.08% DDQ. 
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Table 4.2. Analytical characteristics of the proposed methods 
Parameters Method A Method B 
>^ ax (nm) 
Beer's law limit ((xg ml'') 
Molar absorptivity (I mol'' cm"') 
Regression equation* 
s\ 
±ts% 
s\ 
±ts\ 
Correlation coefficient (r) 
Variance (So'') 
Detection limit (ng ml'') 
535 
10-360 
1.421 X 10^  
A = 3.515X 
6.260X10'^ 
1.480X10'^ 
2.862 X 10"* 
6.769X10-* 
09999 
1.048X10'* 
1.091 
5 10'^  + 2.076 X 10''C A = 2.734 X 10'^ + 1.100 X 10'^  C 
570 
1-65 
7.502 X 10^  
4.587X10"^ 
1.085 X 10"' 
1.191 X 10"^  
2.816X10"^ 
0.9999 
6.408 X lO"'' 
0.161 
'With respect to A = a+bC, where a = intercept, b=slope and C= concentration. 
Standard deviation of the intercept. 
'Confidence interval of the intercept. 
''standard deviation of the slope. 
'Confidence interval of the slope. 
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Fig. 4.9. Calibration curve for determination of amiodarone (method A). 
148 
« 
o 
c 
ni 
o 
in 
n 
< 
-1 
Concentration {p.g ml ) 
Fig. 4.10. Calibration curve for determination of amiodarone (method B). 
149 
confidence level. It confirmed that intercepts for the proposed methods are not 
significantly different from zero. Thus the present methods are fi-ee from 
constant errors independent of the concentration of the amiodarone. 
The detection limit [36] for method A and B were calculated and found 
to be 1.091 and 0.161 ^g ml'', respectively. The small value of the variance 
(1.048 X 10"^  and 6.408 x 10"'' |ig ml'' for method A and B, respectively) 
confirmed the small degree of scatter of experimental data points around the 
line of regression. Both the detection limit and the slope of the calibration 
graphs indicated the good sensitivity. 
The error (Sc) in the determination of a given concentration of 
amiodarone was calculated by using the following expression [37]. 
1/2 
b 
r + _!_+ (A-A)^  1 
The value of Sc may be used to .establish the confidence limit at the selected 
level of significance for the determination of unknown concentrations by 
using the relation C, ± tSc. The results are shown in Figs. 4.11. and 4.12. by 
plotting percentage uncertainty versus the concentration of amiodarone [38] at 
95% confidence level. Hence the confidence limits established for both 
methods (A and B) can be used to evaluate the relative uncertainty directly on 
the concentration over the full range of the concentration tested. 
The reproducibility of the proposed methods were checked by 
estimating three different concentration levels within the Beer's law limit in 
150 
§ 
120 180 240 
Concentration of amiodarone (ng ml"^ ) 
360 
Fig. 4.11. Plot of the variation of the confidence limit at 95% confidence 
level for method A, presented as uncertainty percentage on the 
concentration of amiodarone. 
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Concentartion of amiodarone (jig ml ) 
Fig. 4.12. Plot of the variation of the confidence limit at 95% confidence level for 
method B, presented as uncertainty percentage on the concentration 
of amiodarone. 
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six replicates. Tlie analytical results obtained from this investigation are 
summarized in Table 4.3. The standard deviation, relative standard deviation 
and standard analytical error [39] can be considered to be very satisfactory. 
The validity of the proposed methods for the determination of drug in 
commercial dosage forms was tested by applying standard addition technique. 
In this study a known amount of pure amiodarone was added to preanalyzed 
commercial dosage forms. The recoveries were obtained in the range of 99.98 
- 100.12%. The results are summarized in Table 4.4. The common excipients 
present in formulations did not interfere. 
The applicability of the proposed methods for the determination of 
amiodarone in commercial dosage forms were examined by analyzing 
marketed products such as Aldarone (Zydus Alidac), Amiodar (Cardicare), 
Duron (Samarth), Eurythmic (Troikaa). The results of the proposed methods 
were statistically compared with those obtained by the reference method [21] 
and are summarized in Table 4.5. It is evident from the table that the 
calculated t and F values [40] are less than the theoretical ones at 95% 
confidence level, indicating no significant difference between the methods 
compared. 
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CHapter -5 
Quantitative SpectropHotometric MetHocCsfor 
determination of^erapamidKycfrocHlbncfe in (Drug 
formulations ZJsing (Potassium Metaperiodate and 
TropaeoCin 000 
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INTRODUCTION 
Verapamil hydrochloride i.e. (±)-5-[(3,4-dimethoxyphenethyl) methyl 
amino]-2-(3,4-dimethoxyphenyl)-2-isopropyI valeronitrile monohydrochloride 
is clinically a very useful member of the calcium channel blocker. It is used 
in the treatment of supraventricular arrhythmias, angina and hypertension 
[1-3]. 
The drug and its formulations are officially listed in BP [4], which 
suggests potentiometric titration method, USP [5] recommends a gas 
chromatographic method and IP [6] describes a non-aqueous titration method 
for its assay in bulk and dosage forms. The different analytical methods that 
are reported for its determination include high performance liquid 
chromatography [7-23], high performance thin layer chromatography [24], 
liquid chromatography [25,26], gas-liquid chromatography [27,28], capilllary 
gas chromatography [29,30], potentiometry [31], potentiometry-
conductometry [32], stripping voltammetry [33], atomic emission 
spectrometry [34], mass spectrometry [35] and UV spectrophotometry [36]. 
Although the above methods have adequate sensitivity to assay lower 
concentrations of the drug and hence use of these methods are justified when 
the concentration of drug in biological fluids is low. Moreover, these methods 
are not easily manageable because of high cost technique. The dru<^  
concentrations (40-240 mg per tablet) are high enough in pharmaceutical 
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formulations. Therefore, the need for spectrophotometric method is fully 
justified. 
A review of literature revealed that few spectrophotometric methods 
for the assay of verapamil hydrochloride based on charge transfer complexes 
with 2,3,5,6,-tetrachloro-p-benzoquinone [37], 2,3-dichloro-5,6-dicyano p-
benzoquinone and 2,5-dichloro-3,6-dihydroxy-p-benzoquinone [38], 
chromotrope 2B and chromotrope 2R azodyes [39]; extractable ion-pair 
complexes with bromothymol blue, bromophenol blue, bromocresol green, 
bromocresol purple and methyl orange [40], solochrome black-T, solochrome 
dark blue, fast sulfone FF and solochrome cyanin R [41], erioglaucine and 
indigo carmine [42], alizarin red-S [43], picric acid [44] and oxidation of drug 
with chloramine T in HCl medium [45]. 
This chapter describes two simple, sensitive, fast and economical 
spectrophotometric methods for the assay of verapamil hydrochloride in pure 
and dosage forms. The first method is based on the oxidation of drug with 
potassium metaperiodate in sulphuric acid medium. The second method 
utilizes the formation of an ion-pair complex of the drug with tropaeolin 000 
and subsequent extraction of the yellow colour into chloroform under reaction 
conditions used. 
E X P E R I M E N T A L 
Apparatus 
A Milton Roy Spectronic 200"" spectrophotometer (USA) and an Elico 
model Ll-10 pH meter were used for absorbance and pH measurements, 
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respectively. A water bath shaker (NSW 133, India) was used to control the 
heating temperature for colour development. 
Reagents and Standards 
All chemicals and reagents used were of analytical grade or 
pharmaceutical grade. All solutions were prepared in doubly distilled water. 
Aqueous solutions of potassium metaperiodate (0.2%; Otto chemie, India), 
tropaeolin 000 (0.05%, Fluka), and 10 M sulphuric acid (Merck, India) were 
prepared. 
A buffer solution of pH 4 was prepared by mixing 50 ml of 1.0 M 
sodium acetate solution with 39.5 ml of 1.0 M HCl solution and diluted to 250 
ml with doubly distilled water [46]. The pH of the solution was adjusted to an 
appropriate value with the aid of a pH meter. 
Verapamil hydrochloride was kindly gifted by Samarth Pharma Pvt. 
Limited, India. The standard solutions of verapamil hydrochloride (2.5 mg 
ml'^  and 0.4 mg ml"') were prepared in doubly distilled water. 
Recommended Procedures 
Method A 
Into a series of boiling test tubes different concentrations of verapamil 
hydrochloride (0.00 - 0.75 ml; 0.25%) solution were pipetted. To each test 
tube 1.2 ml of potassium metaperiodate and 5 ml of 10 M H2SO4 were added, 
mixed well and placed on a water bath maintained at 100±1°C for 18 min. The 
solutions were cooled to room temperature and transferred to a 10 ml standard 
volumetric flask. The contents were diluted to volume with doubly distilled 
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water. The absorbance was measured at 425 nm within the stability period of 
2 hr. against the reagent blank treated similarly. 
Method B 
Into a series of 50 ml separating funnels different volumes of 0.04% 
drug solution containing up to 300 \ig were pipetted. 5 ml of buffer solution 
of pH 4 and 2 ml of tropaeolin 000 were added to each separating funnel and 
mixed well. The funnels were shaken with 10 ml chloroform for 2 min for 
complete extraction and then allowed to separate the two layers. The 
absorbance of the chloroform layer was measured at 400 nm against a reagent 
blank treated similarly. The colour is stable for at least 3 hr. 
Analysis of Pharmaceutical Formulations 
Twenty tablets were powdered and mixed thoroughly. An amount 
equivalent to 250 mg of verapamil hydrochloride was weighed accurately. It 
was stirred with chloroform and filtered through Whatmann No. 42 filter 
paper. The residue was washed well with chloroform for complete recovery of 
the drug. The chloroform was evaporated to dryness and the left drug was 
dissolved in doubly distilled water and diluted to 100 ml with doubly distilled 
water. It was further diluted according to the need and then analyzed 
following the recommended procedures. 
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RESULTS AND DISCUSSION 
Potassium metaperiodate is a well known oxidant and has been used for 
the oxidation of p-blockers [47-48] containing amino group. The oxidation 
products were arylaldhyde or aryloxyacetaldehyde, and secondary or tertiary 
butylamine [47]. In all such studies, the presence of a methyl or methylene 
group attached to nitrogen is the basic need [49] so that >N—CH2 linkage in 
tertiary amines was cleaved preferentially by an oxidant (potassium 
metaperiodate or chloramine T or N-bromosuccinimide) resulting in the 
formation of yellow coloured product. The oxidation of verapamil 
hydrochloride with potassium metaperiodate was carried out in aqueous 
sulphuric acid medium as it fulfills the basic need of having tertiary amine 
with >N-CH2 linkage. Therefore, >N-CH2 linkage was cleaved preferentially 
resulting in the formation of aryloxyacetaldehyde and secondary amine. The 
oxidation product absorbs maximally at 425 nm (Fig. 5.1.). In order to 
establish stoichiometric ratio between verapamil hydrochloride and potassium 
metaperiodate, the method of continuous variations [50] has been applied and 
was found to be 1:1 (Fig. 5.2.). On isolation of the two major products, one 
produces a blue colour when treated with a benzene solution of chloranil 
confirming the presence of amino group and other product reacts with 2,4,-
dinitrophenyl hydrazine to give yellow coloured product indicating the 
presence of aryloxy benzene acetaldehyde. It has been confirmed that iodine 
was not evolved during this reaction. 
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0.50 
400 450 
Wavelength (nm) 
550 
Fig. 5.1. Absorption spectrum of the reaction product of Verapamil 
hydrochloride with potassium metaperiodate. 
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Mole fraction of drug (XQ) 
Fig. 5.2. Job's plot for the reaction of verapamil hydrochloride with 
potassium metaperiodate (each 5. 09 x 10"^  M). 
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Therefore, based on the literature background and our experhiiental 
findings, the reaction mechanism was proposed and given in Scheme 5.1. 
Verapamil forms coloured chloroform extractable ion-pair complex in 
acidic buffer with tropaeolin 000. The absorption spectrum of the ion-pair 
complex, which absorbed maximally at 400 nm, is shown in Fig. 5.3. The 
reagent blank under similar conditions showed no absorption. The molar ratio 
between verapamil and tropaeolin 000 is established by Job's method [51]. 
This measurement (Fig. 5.4.) showed that 1:1 complex was formed between 
drug and tropaeolin 000. 
Verapamil hydrochloride contains tertiary amino group which is 
protonated in acid buffer, while sulphonic acid group in tropaeolin 000 is the 
only group undergoing dissociation in the pH range of 0.5 - 6.9. Finally the 
protonated verapamil hydrochloride forms ion-pair with tropaeolin 000, which 
is quantitatively extracted into chloroform. The possible reaction mechanism 
is proposed and given in Scheme 5.2. 
Optimization of Variables 
The optimum conditions for the assay of verapamil hydrochloride were 
established via a number of preliminary experiments. 
Method A 
Effect of heating time 
To investigate the optimum heating time for color development, 0.75 
ml of 0.25% verapamil hydrochloride was mixed with 5 ml of 10 M 
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Wavelength (nm) 
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Fig. 5.3. Absorption spectrum of the reaction product of 
Verapamil hydrochloride with tropaeolin 000. 
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Mole fraction of drug (XQ) 
Fig. 5.4. Job's plot for the reaction of verapamil liydrochloride with 
Tropaeolin 000 (each 1.02 x 10'^ M). 
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H2SO4 and 1.2 ml of 0.2% potassium metaperiodate into a boiling test tube. 
The content of the mixture was heated for 20 min. on a water bath at 
100±1°C. The intensity of the color (Fig. 5.5.) was reached to maximum after 
17 min of heating and remained constant and therefore 20 min of heating time 
was used throughout the experiment. 
Effect of potassium metaperiodate 
To 0.75 ml of 0.25% verapamil hydrochloride, different volumes (0.5 -
1.5 ml) of 0.2% potassium metaperiodate and 5 ml of 10 M H2SO4 were 
added. The reaction mixtures were heated for 20 min on a water bath at 
100+1°C. The reaction mixture was diluted to 10 ml with doubly distilled 
water and the absorbance was measured against a reagent blank at 425 nm. 
The results (Fig. 5.6) showed that the highest absorbance was obtained with 
1.0 ml, which remained unchanged with higher amount of potassium 
metaperiodate. Thus, 1.5 ml of the reagent was added for colour 
measurements. 
Effect of the concentration of sulphuric acid 
The influence of the yolume of 10 M H2SO4 on the formation of yellow 
colour was. studied. This was performed by pipetting 0.75 mi of verapamil 
hydrochloride (0.25%), 1.5 ml of potassium metaperiodate and different 
volumes (1-5 ml) of 10 M H2SO4. It is evident from Fig. 5.7. that the 
maximum absorbance was obtained with 4.7 ml of 10 M H2SO4 above this 
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173 
0.7 
0.6 -I 
0.5 
• - • - • • 
-r 
2 
Volume (ml) 
Fig. 5.6. Effect of the volume of 0.2% potassium 
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volume, the absorbance remains constant. Therefore, 5.0 ml of 10 M H2SO4 
was used for all the measurements. 
Method B 
Effect of the concentration of tropaeolin 000 
The effect of the volume of 0.05% tropaeolin 000 was studied in a 
series of 50-ml separating funnels containing 30 |J.g ml"' of verapamil 
hydrochloride, 5.0 ml of buffer solution of pH 4 and different volumes of the 
reagent. 10 ml of chloroform was used to extract the ion-pair complex. It is 
apparent from Fig. 5.8. that the maximum absorbance was found with 1.9 ml 
of tropaeolin 000, beyond which absorbance was constant. Thus, 2.5 ml of 
tropaeolin 000 was used for ion-pair formation throughout the experiment. 
Effect of the pH 
The influence of pH of the buffer solution of sodium acetate HCl on 
the formation of extractable ion-pair complex of the drug with tropaeolin 000 
was studied. The results are shown in Fig. 5.9. It is evident form the figure 
that the absorbance of the complex with tropaeolin 000 was found to be 
constant within the pH range 3.5 - 4.5. Thus, all the absorbance measurements 
were made at pH 4. 
Choice of organic solvent and time of shaking 
A variety of organic solvents such as benzene, toluene, hexane, 
chloroform, carbon tetrachloride, ethyl acetate and 1,2-dichloromethane were 
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Fig. 5.8. Effect of the volume of 0.05% tropaeolin 000. 
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examined for an applicable extraction procedure, but chloroform was 
preferred for its selective extraction of the ion-pair complex from the aqueous 
solution. 
The time of shaking for complete extraction of ion-pair complex was 
studied and found that the absorbance of the extract remains constant between 
0.5 - 4.0 min. Thus, 2.0 min shaking time was utilized as an optimum value 
throughout the experiment. The ion-pair complex was quantitatively 
recovered in one extraction only. 
Interference studies 
The effect of excipients and additives commonly used in drug 
formulations, such as starch, lactose, talc, stearic acid, magnesium stearate, 
titanium dioxide, tartrazine and lactic acid was evaluated using the proposed 
methods. It was found that the common excipients and additives did not 
interfere with the analysis. 
Analytical data 
Under the optimized experimental conditions, linear calibration graphs 
(Figs. 5.10. and 5.11.) were obtained over the concentration ranges 0.00 -
187.5 and 2-30 ]xg ml"' of verapamil hydrochloride with molar absorptivities 
of 1.18 X 10^ and 9.82 x 10^ 1 mof'cm"' using method A and B, respectively. 
Table 5.1. summarizes the analytical parameters such as Beer's law limit, 
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Fig. 5.10. Calibration curve for determination of verapamil 
hydrochloride (method A). 
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Concentration (ngml ) 
Fig. 5.11. Calibration curve for determination of verapamil 
hydrochloride (method B). 
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calibration equations obtained by least square treatment of calibration data, 
coefficient of correlation, variance and confidence limit for slope and 
intercept. The correlation coefficient was found to be 0.9999 and 0.9998 for 
method A and B, respectively, indicating the good linearity of both the 
calibration graphs and the intercepts are all close to zero. Test of significance 
of the intercept of the regression line showed that the experimental intercept, 
a, does not differ significantly from the theoretical value, zero. For this, a 
simplified method was used to calculate the quantity from the relation t = a/Sa 
[52] and its comparison with the tabulated data from the t-distribution. The t-
value for method A and B are 0.200 and 0.190, respectively which do not 
exceed the tabulated t-value (t = 2.365, when v = 7) at 95% confidence level. 
It confirmed that intercepts for the proposed methods are not significantly 
different from zero. Thus the present methods are free from constant errors 
independent of the concentration of the verapamil hydrochloride. 
The detection limit [53] and variance were found to be 0.772 |a,g ml"', 
7.01 X 10"' |ig ml"' and 0.396 ^g ml"', 1.28 x 10"^  i^ g ml"' for method A and B, 
respectively. The small value of variance obtained for both the methods 
pointed towards negligible scattering of experimental data points around the 
line of best fit. 
The statistical analysis of the calibration data has been used to 
calculate error (Sc) in the determination of a given concentration of verapamil 
hydrochloride and also provides a way to establish the confidence limits at the 
selected levels of confidence to estimate the relative uncertainty of the 
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concentration over the full range of the concentration tested. These 
parameters were established by using the relation [54], 
^'~ b 
1 1 {A-Af 1 + - + - ^ 
» b'Yic-cf 
1/2 
Where A and C are average values of the absorbance and concentration, 
respectively, for n standard samples. Figs. 5.12. and 5.13. shows the graphs of 
Sc versus concentration of verapamil hydrochloride. The minimum error is 
obtained on the determination of about 100 and 16 [ig ml'^  of verapamil 
hydrochloride for method A and method B, respectively. 
The accuracy and precision of the proposed methods were evaluated by 
the replicate analyses at the three different concentration levels. The results 
are summarized in Table 5.2. The relative standard deviation and standard 
analytical error were found to be 0.130-1.038% and 0.018-0.102 fag mV\ 
respectively. The results, therefore, indicated that the precision and accuracy 
of the proposed methods were satisfactory. 
To check the validity of the proposed methods using standard addition 
technique, a fixed amount of pure drug was added to the preanalysed drug 
formulations. The results are summarized in Table 5.3. The recovery results 
were quite satisfactory. 
The applicability of the proposed methods were compared with the 
reference method [43] by analyzing authentic commercial products of 
verapamil hydrochloride such as Calaptin 80 so (Nicholas Piramal), Verap 80 
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Fig. 5.12. Error in the determination of verapamil hydrochloride 
using statistical analysis of standard calibration data with 
potassium metaperiodate. 
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(Mano Pharma) and VPL Amp. 05/2 ml (Samarth Pharma); the results are 
summarized in Table 5.4. The results of the proposed methods were statistically 
compared with those obtained by the reference method. It is evident from Table 
5.4. that the calculated t- and F-values are less than the theoretical ones [55] at 
the 95% confidence level, which indicates no significant difference between the 
methods compared. 
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Ug^-
A new simple and sensitive kinetic spectrophotometric method for the detemiinatlon of silymarin in 
pure form and in pharmaceutical fomnulations Is described. The method Is based on the oxidation of 
the drug with potassium permanganate at pH 7.0 db 0.2. The reaction is followed spectrophotometri-
cally by measuring the decrease in the absorbance at 530 nm. The calibration graph Is linear in the 
7ange of 1 8 - 5 ( ^ ml"''. The method has been successfully applied to the determination of silymarin 
In pharmaceutical formulations. Statistical comparison of the results with the reference method shows 
excellent agreement and Indicates no significant difference in accuracy and precision. 
1. Introduction 
Silymarin 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-niethoxy 
phenyI)-2-(hydroxy-methyI)-l,4-benzodioxan-6-yl]-4-chro-
manone, is an important antihepatotoxic drug whicli is ob-
tained from tlie dried fruits of Silybum marianum and 
widely used for tlic treatment of hepatic disorders (Cava-
lieri 1974; Salmi and Sama 1982; Ferenci etaL 1989; 
Hruby 1983). The drug is officially listed in Martindale 
The Extra Pharmacopoeia (Martindale 1996). 
The assay procedure listed in the monograph of the Italian 
pharmacopoeia describes the UV-\^s spectrophotometric 
method (Farmacopoeia 1985) for deteimination of the drug . 
in bulk and pharmaceutical formulations. Several other 
methods have been employed to determine silymarin in bio-
logical specimens and/or pharmaceutical formulations such 
as high performance liquid chromatography (Martinelli 
etal. 1991; Marcher and Kikuta 1993; Rickling etal. 1995; 
Tittel and Wagner 1977; Tittel and Wagner 1978; Quercia 
etal. 1980; Quercia etal. 1983; Steinigen 1983; Law and 
Das 1987; Tomov etal. 1985; Pashankov 1988; Nikolov 
1990; Kurkin 1996; Wang et al. 1998), thin layer chromato-
graphy (Lin 1982; Abdel-Salam 1982; Vanhaelen and Van-
haelen-Fastre 1983;Heinz etal. 1985; Wu and Wang 1989; 
Lin etal. 1998; Szilarjtes-Obeiglo and Kowalesioska 1984), 
high performance thin layer chromatography (Funk et al. 
1987), potentiomeuic tiu-ation (Koerbl et al. 1983), diffuse-
reflectance fourier transform infraied specU'oscopy (Marti-
nez et al. 1991) and UV spectrophotometry (Lan et al- 1983^ 
Belikov 1985). 
In the literature only few spectrophotometric methods 
have been reported. The drug content in pharmaceutical 
formulations was detennined (Zarapkar et al. 2000), based 
on the formation of a coloured complex of the drug with 
2,4-dinitrophenyl hydrazine, in the presence of tetramethyl 
amincjJiydroxid-\Qualitativc' detemiinations aie done at 
490 nm. Another'spectrophotometric method for the csti-
mation of silymarii^based on its reaction with diazotized 
sulfanilic acid in alkaline medium to form an orange-red 
coloured chromogen which absorbed maximally at 460 nm 
(Rajasekaran 1997). Reddy etal. (2001) have reported two 
spectrophotometric methods for silymarin determination. 
The first method was based on the oxidation of the drug 
by Fe(III) and estimating the reduced Fe(II) with 1,10-
phenanthroline at 510 nm. The other method involved the 
formation of a blue complex on treatment with Folin-Cio-
calteau reagent in the presence of NaOH and subsequent 
determination was done at 740 nm. These methods are 
somewhat tedious and time consuming. Therefore, we 
develop^ed a fast, low cost and selective method for rou-
tine analysis of silymarin in bulk and drug formulations. 
The extent of oxidation of organic substrate by potassium 
permanganate depends on the pH of the rnedium. TTie 
heptavalent manganese changes to Mri(lV).)^n~"aIkaline 
medium while in neutral and acidic mediurn^the permaii-
ganate is further reduced forming ultimately Mn(II). This 
behaviour of permanganate has been exploited to develop 
a kinetic spectrophotometric method for assay of nifedi-
pine in drug formulations (Rahman and Azmi 1999). 
The present communication describes a method for the as-
say of silymarin in bulk and pharmaceutical formulations. 
The method is based on the oxidation of silymarin by potas-
sium permanganate at pH 7.0 ± 0.2 and the course of the 
reaction was followed by measuring a decrease in absor-
bance at 530 nm. 
2. Investigations, results and discussion 
The oxidation of organic compounds by permanganate is 
dependent upon the pH of the medium. During the course 
of the reaction the valence of manganese changes and in-
tennediate ions have been suggested as participating oxi-
dants. But which species have the main role as potential 
oxidants depends on the nature of the substrate and pH of 
•' • o'^ . • C- r/.-'/i 
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Rg. 1: Absorbance-time curves: KMn04, 4.8 x 10 *M and silymarin (a) 
3.731 X 10-5 M; (j,) 4.146 x 10' 'M; (c) 6.219x10-'; (d) 
8.292 x 10-5 M; (e) 10.365 x 10"'M 
the medium. The oxidation of silymarin by potassium per-
manganate at pH 7.0 ± 0.2 was followed spectrophotome-
trically at 530 nm. The absorbance-time curves are shown 
in Figs. 1 and 2, which are all sigmoid in nature through-
out the entire range and therefore, the initial rates of reac-
tion were determined from the slope of the initial tangent 
to the absorbance-time curves. The order with respect to 
permanganate was determined by studying the reaction at 
different initial concentrations of permanganate with fixed 
silymarin concentration. Keeping the silymarin concentra-
tion higher than that of the oxidant, the plot of initial rate 
[-d[A]/dt] against initial absori)ance was linear passing 
through the origin suggested that the order of reaction 
with respect to permanganate at the start is one. The order 
with respect to silymarin was evaluated from the measure-
ment of the rates at several concentrations of silymarin but 
at fixed concentration of KMn04 which was also found to 
be one. The first order dependence on both permanganate 
and silymarin in the initial stages leads to the simple rate 
expression: 
Rate = K[silymarin] [MnO^] (1) 
Silymarin is a naturally occurring aryl chromanone(l) re-
lated to flavanone. The flavanones are 2,3-dihydro deriva-
tives of flavones, which are readily interconvertible. 
Though the basic skeleton of flavanone and flavone is the 
same, the key which distinguishes one structural type 
from another is the oxidation level of the various carbons 
in the heterocyclic ring. The flavones are in a high state 
of oxidation whereas tlavanones are in low state of oxida-
Scheme 1 
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Fig. 2: Absoibance-lime curves: silymarin, 10. 365 x 10 ' M and KMn04 
(a) 3.00 x 10-^ M; (b) 2.10 x 10"^ M; (c) 1.50 x 10"^ M; (d) 
9.00 X 10-5 M 
tion. The oxidation of flavanone to flavone with a variety 
of reagents such as selenium dioxide (Sammel 1979) or 
triphenyl methyl carbonium ion (Schonberg and Schutz 
1960) has been reported. In this study, the same mechan-
ism seems to be involved. The oxidation of silymarin by 
permanganate takes place at pH 7.0 ± 02 leading to the 
formation of chromone(2). Thus, the dehydrogenation is 
effected by permanganate and consequently disproportio-
nation between inmiediate oxidation states of manganese 
results in the formation of MnOa. However no precipita-
tion of Mn02 was observed under study time period. The 
reaction mechanism is presented in the Scheme. 
Under the optimum experimental conditions, a caUbration 
curve was constructed by plotting logarithm of initial rate 
of reaction (log v) versus logarithm of silymarin concen-
tration (log C), which showed a linear relationship over 
silymarin concentration range of 18-50 ng • ml"'. TTie Un-
ear regression analysis using the method of least square 
was made to evaluate the slope, intercept and correlation 
coefficienL The linear regression equation and correlation 
coefficient are log v = 1.024 log C +3.235 and 
r = 0.9997 which indicates an excellent linearity. The con-
fidence Umits for the slope of the line of regression and 
intercept were computed using the relation b ± tSb and 
a ± tSa (Miller 1991), at 95% confidence level and found 
to be 1.024 ± 3.96 x 10"^ and 3.235 ± 1.67 x 10"', re-
spectively. This indicated the high reproducibility of the 
kinetic method proposed. Linearity was also evaluated 
(Torrado etal. 1994) from the relative standard deviation 
of the slope of the caUbration line and found to be 1.215. 
OH 0 
,0. ^CHjOH + Mn04 
OH O OH 
I 
+ HO-Mn—0 
Chromiinone (1) Chronione (2) 
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1.30 
128-
126-
124-
O 122-
>< 1.20-
r 118 
HI 1.16-
1.14-
112 
1.10 
Table 1: Precision test of the proposed kinetic method 
10 
—r— 
20 
—T— 
30 40 60 
Concentration of silymarin (PQ -mV) 
Rg. 3: Eiror in the detenninalion of the concentration of silymarin using 
statistical analysis of standard calibration data 
The limit of detection was established using the equation 
(Morelli 1983, NaHmov 1963): 
Limit of detection (.2 r^-lV" 7 (2) 
where n is the number of standard samples, t is the value 
of student's t for n—2 degrees of freedom at 95% confi-
dence level and Si = variance. The variance and detection 
limit were calculated to be 1.100 x 10~* ng • ml~* and 
2.823 X 10"^ [ig • ml"' respectively, which confinned neg-
ligible scattering of experimental data points around the 
line of regression and good sensitivity of the method. 
The error (Sc) in the determination of a given concentra-
tion of silymarin (C) was established using the equation 
(MorelU 1987): 
Sc .So 
• b n b2(2 C2 - nC') 
1/2 
(3) 
Where y and C are average ordinate and abscissa values, 
respectively, for n standard samples. Fig. 3 shows the 
4S-, 
4 0 
3 5 ' 
S 3 0 -
o as ^ 
o 
< 
15-
lo-
os-
10 
— I — 
20 30 
— 1 — 
40 
— I 
50 
Concentration of silymann (ng -mr^) 
Fig 4 Variaiion of the confidence limit ai (a) p = 0 05 and (b) p = 0 01 
level of significance in ihe form of uncertainly percentage on the 
conccniralion of iilymann 
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Sample No Imiial rate of reaciion 
(mol t"' mm"') 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 4x 10-2 
11.5 X 10-^ 
11.3 X 10-2 
n.3 X 10-2 
11.5 X 10-2 
11.5 X 10-2 
11.2 X 10-2 
11.4 X 10-2 
11.3 X 10-2 
11.2X 10-2 
402 
404 
400 
399 
406 
405 
396 
401 
398 
397 
Mean percent recovery = 100% 
Relative standard dcviauon = 0 8% ' 2 ^ ;< lo 
graph of Sc versus the concentration of silymarin. It is 
apparent from the graph that the error is reached mini-
mum when the actual initial rate was equal to the average 
initial rate in the calibration, graph. 
The minimum error of^^^^310^|ig • m r ' was found in 
the determination of abouTSO ng • ml~^ silymarin. The va-
lue of Sc also allows establishing the confidence limit at 
the selected level of significance for the determination of 
unknown concentrations by using the relation, C, ± tSc. 
The results are shown graphically (Fig. 4) in the form of 
percent uncertainty ih^ on the concentration at 
95% and 99% confidence levels. This is a useful way of 
expressing the confidence limits because the relative un-
certainty can be estimated directly on the concentration 
over the full range of the concentration tested. 
The reproducibility was established for ten independent 
analyses of solution containing 0.40 mg silymarin. The ana-
lytical results obtained fi-om the investigation are summar-
ized in Table 1. The relative standard deviation and mean 
percent recovery were 0.87% and 100.3%, respectively and 
considered to be very satisfactory. The validity of the pro-
posed kinetic method was checked by applying standard 
addition method and the results are reported in Table 2. 
The applicability of the proposed method for the determi-
nation of silymarin in dosage forms was examined by ana-
lyzing marketed products; the results were compared to 
those obtained by the reference method (Rajasekaran et al. 
1997) and are summarized in Table 3. The performance of 
the proposed method was judged by calculating t- and F-
values (Christian 1986). At 95% confidence level judged, 
the calculated t- and F-values do not exceed the theoreti-
cal values indicating no significant difference between the 
proposed kinetic method and the reference method. 
Table 2: Determination of silymarin in pharmaceutical formu-
lations by the standard addition method 
Preparation Amount taken Amount Total amount 
(Hg ml- ' ) otitied - / found (lie ml' 
. f/l^>,fn( I 
Recovery RSD 
') (%) (%)' 
Silybin-70 
(tablet) 
Silvia-70 
(tablet) 
Limann-70 
(capsule) 
Sivylar-70 
(capsule) 
Levalon-70 
(capsule) 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
10 
20 
)0 
20 
10 
20 
10 
20 
20 0 
39 9 
20 0 
40 0 
20 0 
40 0 
20 0 
40 0 
20 0 
39 9 
100 1 
99 9 
100 1 
100 0 
100 I 
100 2 
100 1 
100 0 
1002 
99 9 
0 35 
0 34 
0 47 
0 22 
0 58 
0 46 
0 57 
0 22 
0 68 
0 34 
Pifi-c intlt.pLnd(.n[ Jtnl\se\ 
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Table 3: Determination of silymarin in dosage fonns by the kinetic method proposed and by the reference metliod 
Preparation 
Silybin 
(tablet) 
Silvia 
(tablet) 
Limarin 
(capsule) 
Sivylar 
(capsule) 
Levalon (capsule) 
Labelled amount) 
(mg/tablct or capsule) 
70 
70 
70 
70 
70 
Proposed 1 
Recovery 
(%) 
100 0 
100.1 
100 0 
100.1 
99 9 
uneuc method 
SD 
0 13 
0 09 
0.09 
0.12 
0 05 
RSD 
0 33 
0.23 
0 24 
0 30 
0.13 
Reference method 
Recovery 
(%) 
99 8 
100.1 
99.6 
100.0 
100.3 
SD 
0 09 
0.06 
0.13 
0 06 
0.10 
RSD (%)• 
0 23 
0 15 
0 32 
0 15 
0.26 
0.452 
0 205 
1 147 
0 227 
1268 
Fcfc 
2.010 
2 340 
1751 
3 940 
3.830 
• Five independent analyses 
' Thcorcucal value for t at 95% confidence level is 2 776 
= Ihcortacal value for F at 95% confidence level is 639 
In conclusion, the proposed method is fast, simple and sen-
sitive for the determination of silymarin in bulk and com-
mercial formulations with good accuracy and precision. The 
sensitivity is very high and compares favourably with that 
of other known methods and, can therefore (6^n}success-
fully applied as an alternative to the existing nieEods>, 
3. Experimental 
3.1. Apparatus 
The absotbance was measured on a spectronic 20 D"*" spectrophotometer 
(Milton Roy, USA) with 1 cm glass cells 
3.2. Reagents 
All chemicals used were of analytical or pharmaceutical grade Potassium 
permanganate, 0.003M was freshly prepared by dissolving 47.41 mg of 
potassium permanganate in 100 ml of doubly disalled water. The apparent 
purity of the potassium permanganate solution was checked titiimetrically 
(Vogel 2002) 
3.3 Test solution 
Silymarin (J mg • ml"') (Micro Labs, Bangalore, India) was dissloved in 
methanol. 
3.4. Procedure 
341. Stlymarin 
Aliquots of 0 18-0 50 ml of silymarin standard test solution were pipetted 
info a senes of 10 ml sumtiaid volumelnc flasks To each staniiaid flask 1 6 ml 
of 0 003 M potassium permanganate was added and then diluted to volume 
with doubly distilled water at 30 ± 1 °C. After mixing, reaction mixture was 
immediately transfened to a spectrophotometric cell and the decrease in ab-
sorbance was recorded as a funcuon of time for 20 rmn at 530 nm The initial 
rate of the reaction (v) at different concentrations was obtained from the slope 
of the tangent to the absorbance-time curve The calibration curve was con-
structed by plotung the loganlhm of the mitral rate of reaction (log v) versus 
logarthm of the concentration of the silymann (log C) 
342 Silymann in pharmaceiilicalformulalions 
An accurately weighed quantity of the mixed contents of five capsules or 
five powdered tablets, equivalent to 50 mg of the drug, was extracted into 
50 ml chloroform with shaking and the residue was filtered using What-
man No 42 filter paper The filtrate was evaporated to dryness and the 
residue was taken up with methanol and transferred to a 50 ml standard 
volumemc flask, diluting to volume The assay was completed following 
the recommended procedure 
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